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ABSTRACT 
The leading cause of death in the Western world continues to be coronary heart 
disease (CHD). At the root of the disease process is dyslipidemia – an aberration in 
the relevant amounts of circulating blood lipids. Cholesterol builds up in the arterial 
wall and following rupture of these plaques, myocardial infarction or stroke can 
occur. Heart disease runs in families and a number of hereditary forms are known. 
The leading cause of adult dyslipidemia presently however is overweight and 
obesity. This thesis work presents an investigation of the molecular genetics of 
common, hereditary dyslipidemia and the tightly related condition of obesity. 
 
Familial combined hyperlipidemia (FCHL) is the most common hereditary 
dyslipidemia in man with an estimated population prevalence of 1-6%. This 
complex disease is characterized by elevated levels of serum total cholesterol, 
triglycerides or both and is observed in about 20% of individuals with premature 
CHD. Our group identified the disease to be associated with genetic variation in the 
USF1 transcription factor gene. USF1 has a key role in regulating other genes that 
control lipid and glucose metabolism as well as the inflammatory response – all 
central processes in the progression of atherosclerosis and CHD. The first two works 
of this thesis aimed at understanding how these USF1 variants result in increased 
disease risk. Among the many, non-coding single-nucleotide polymorphisms (SNPs) 
that associated with the disease, one was found to have a functional effect. The risk-
enhancing allele of this SNP seems to eradicate the ability of the important hormone 
insulin to induce the expression of USF1 in peripheral tissues. The resultant changes 
in the expression of numerous USF1 target genes over time probably enhance and 
accelerate the atherogenic processes. 
 
High-density lipoprotein (HDL) is responsible for the transport of excess cholesterol 
from peripheral tissues to the liver for excretion in bile. This process is termed the 
reverse transport of cholesterol. An inverse correlation exists between the levels of 
HDL-C and the risk for CHD. High levels of HDL-C protect against atherosclerosis 
and this protection is decreased in patients with low HDL-C levels. The ABCA1 
cholesterol transporter is instrumental in the initial transfer of cholesterol from cells 
to the nascent HDL particle for transport to the liver. In the third work of this thesis 
we investigated the early steps of the reverse transport of cholesterol in Finnish 
families with familial low-HDL-C to determine whether a defect there was involved 
 in the increased risk in these families for developing CHD. The role of ABCA1, 
critical to this process, was investigated in patients as well as healthy control 
subjects. Patients with low-HDL-C were found to carry rarer DNA variants (SNPs) 
significantly more often than healthy subjects and sets of these SNPs were related 
dose-dependently to HDL-C levels. While patient-derived macrophages were only 
marginally poorer at the efflux of cholesterol, they exhibited significantly higher 
ABCA1 expression levels. It follows, that the cholesterol efflux capability of 
patient-derived cells in proportion to the ABCA1 expression was markedly lower. 
These results suggest that genetic variation within the ABCA1 gene and defective 
function of the protein are potential contributors to the impaired RCT process in 
Finnish families with low-HDL-C.  
 
Dyslipidemias often represent an outcome of obesity and in the final work of this 
thesis we wanted to address the metabolic pathways related to acquired obesity. It is 
recognized that active processes in adipose tissue play an important role in the 
development of dyslipidemia, insulin resistance and other pathological conditions 
associated with obesity. To minimize the confounding effects of genetic differences 
present in most human studies, we investigated a rare collection of identical twins 
that differed significantly in the amount of body fat. In the obese, but otherwise 
healthy young adults, several notable changes were observed. In addition to chronic 
inflammation, the adipose tissue of the obese co-twins was characterized by a 
marked (47%) decrease in amount of mitochondrial DNA (mtDNA) – a change 
associated with mitochondrial dysfunction. The catabolism of branched chain amino 
acids (BCAAs) was identified as the most down-regulated process in the obese co-
twins. A concordant increase in the serum level of these insulin secretagogues was 
identified. This hyperaminoacidemia may provide the feed-back signal from insulin 
resistant adipose tissue to the pancreas to ensure an appropriately augmented 
secretory response. The down regulation of BCAA catabolism correlated closely 
with liver fat accumulation and insulin. The single most up-regulated gene (5.9 fold) 
in the obese co-twins was osteopontin (SPP1) – a cytokine involved in macrophage 
recruitment to adipose tissue. SPP1 is here implicated as an important player in the 
development of insulin resistance. 
 
These studies of exceptional study samples provide better understanding of the 
underlying pathology in common dyslipidemias and other obesity associated 
diseases –important for future improvement of intervention strategies and treatments 
to combat atherosclerosis and coronary heart disease. 
 
 
Keywords: Complex disease genetics, dyslipidemia, cardiovascular disease, obesity, 
USF1, insulin resistance, FCHL, hypoalphalipoproteinemia 
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TIIVISTELMÄ 
Sydän- ja verisuonitaudit ovat edelleen suurin yksittäinen kuolinsyy länsimaissa. 
Keskeinen riskitekijä on elimistön häiriintynyt rasva-aineenvaihdunta ja veren 
epänormaali rasvapitoisuus, dyslipidemia. Kolesterolia kertyy verisuonien seinämiin 
muodostaen ahtauttavia plakkeja, jotka revetessään voivat aiheuttaa sydäninfarktin. 
Sydän- ja verisuonitaudit esiintyvät suvuittain, ja tunnetaankin useita periytyviä 
dyslipidemian muotoja. Yleisin aikuisiän dyslipidemian syy löytyy kuitenkin 
ylipainosta ja lihavuudesta. Tässä väitöskirjatutkimuksessa on  selvitetty yleisten, 
perinnöllisten dyslipidemioiden molekyyligeneettistä taustaa, ja niihin vahvasti 
liittyvää lihavuutta. 
 
Familiaalinen kombinoitu hyperlipidemia (FKH) on yleisin perinnöllisistä 
dyslipidemioista ja sen arvioitu esiintyvyys länsimaiden väestöissä on 1-6%. Tämän 
alunperin Suomessa kuvatun monitekijäisen taudin taustalla on lukuisten eri geenien 
ja ympäristön yhteisvaikutus. FKH:n liittyvät kohonneet veren kolesteroli- ja/tai 
triglyseridiarvot ja se löytyy jopa 20 %:lla varhaisen sydäninfarktin  sairastaneista. 
Tutkimusryhmämme paikallisti taudille altistavan USF1 geenin, jonka on sittemmin 
näytetty altistavan sydän- ja verisuonitaudille myös väestötasolla. USF1-geeni 
koodittaa muita geenejä säätelevää transkriptiotekijää ja sillä on tärkeä rooli 
elimistön rasva- ja sokeriaineenvaihdunnan sekä tulehdusreaktion säätelyssä. 
Väitöskirjatutkimuksen kahdessa ensimmäisessä osatyössä selvitettiin FKH:hon 
liittyvien geenimerkkien merkitystä USF1-geenin toiminnalle. Yhdellä näistä 
yleisistä emäsparin muutoksista paljastui olevan toiminnallinen merkitys. 
Riskialleelin kantajilla USF1-geenin normaali vaste elimistön insuliinihormonille 
vaikuttaa olevan puutteellinen ja tämä heijastuu USF1:n säätelemien geenien 
muuttuneessa ilmentymisessä. Ajan myötä näiden geenien puutteelliset vasteet 
todennäköisesti voimistavat ja kiihdyttävät ateroskleroosin kehittymistä. 
 
HDL-hiukkaset kuljettavat ylimääräistä kolesterolia pois kehon soluista maksaan, 
josta se erittyy sapen mukana ulos.  Tätä prosessia kutsutaan kolesterolin 
käänteiskuljetukseksi. Suurilla veren HDL-kolesterolipitoisuuksilla onkin sydän- ja 
verisuonitaudilta suojaava vaikutus, kun taas pieni HDL-kolesterolipitoisuus on 
itsenäinen riskitekijä sydän- ja verisuonitaudin kehittymiselle. Kolesterolin 
kuljettajaproteiini ABCA1 on tärkeässä asemassa siirtäessään kolestrolia HDL-
hiukkaselle käänteiskuljetuksen ensivaiheissa. Kolmannessa osatyössä tutkittiin 
 tämän ABCA1-geenin ja sen toiminnan osallisuutta taudin kehittymiselle 
suomalaisissa pienen HDL-kolesterolipitoisuuden suvuissa. Potilaat kantoivat 
merkittävästi useammin harvinaisia ABCA1 geenimuotoja kuin terveet verrokit. 
Potilaiden vaahtosolujen kyky siirtää ABCA1-proteiinin kautta kolesterolia ulos oli 
vain rajallisesti madaltunut, mutta samanaikaisesti ABCA1 geenin ilmentyminen oli 
huomattavasti runsaampi. Täten kolesterolin siirtokyky suhteessa ABCA1-geenin 
ilmentymiseen oli potilailla merkittävästi madaltunut. Tulokset viittaavat siihen, että 
suomalaisissa pienen HDL-kolesterolipitoisuuden suvuissa häiriö ABCA1:n 
toiminnassa voi johtaa huonontuneeseen kolesterolin käänteiskuljetukseen ja täten 
altistaa sydän- ja verisuonitaudille. 
 
Dyslipidemiat ovat usein seurausta lihavuudesta. Rasvakudosta ei enää mielletä vain 
staattiseksi varastoksi vaan sen tärkeillä endokriinisillä ja metabolisilla tehtävillä 
ymmärrettään nykyisin olevan vahva yhteys lihavuuden seurauksiin kuten 
dyslipidemiaan ja insuliiniresistenssiin. Neljännessä osatyössä tutkimmekin kuinka 
rasvakudoksen erinäiset metaboliset prosessit ovat häiriytyneet lihavuudessa. 
Geneettisten sekoittavien tekijöiden minimoimiseksi tutkimme harvinaisia, kehon 
rasvakoostumukseltaan huomattavasti eroavia, mutta perimältään samanlaisia 
identtisiä kaksosia. Rasvakudoksen geeniprofileeissa paljastui useita patologisia 
muutoksia jo näissä nuorissa lihavissa, mutta muuten terveissä aikuisissa. Selvien 
tulehdusmerkkien lisäksi lihavien kaksosten rasvakudoksessa havaittiin merkittävä 
(47%) alentuma mitokondriaalisen DNA:n määrässä –muutos joka kuvastaa 
mitokondrioiden energiantuotannon aktiivista alasajoa. Suurin lihavuuteen liittyvä 
muutos oli haaraketjuisten aminohappojen katabolian aleneminen. Lihavien veressä 
havaittiin vastaavasti näiden insuliinineritystä lisäävien aminohappojen pitoisuuden 
nousu. Tämä saattaa edustaa insuliiniresistentin kudoksen palautesignaalia haimalle 
lisäerityksen aikaansaamiseksi. Kataboliareitin aktiivisuus korreloi vahvasti myös 
maksan rasvan määrän ja insuliiniresistenssin kanssa. Lisäksi osteopontiinin (SPP1) 
havaitiin olevan eniten (5,9 -kertaisesti) yli-ilmentyvä geeni lihavuudessa. Tämän 
rasvakudokseen makrofageja rekrytoivan sytokiinin havaittiin täten liittyvän 
tärkeällä tavalla insuliiniresistenssin syntyyn. 
 
Väitöskirjatutkimusen tulokset syventävät ymmärrystä yleisten dyslipidemioiden ja 
muiden lihavuuteen liittyvien tautien molekyylitason mekanismeista luoden pohjaa 
ateroskleroosin sekä sydän- ja verisuonitaudin hoidon jatkuvalle kehitykselle. 
 
 
 
 
Avainsanat: Kompleksitautigenetiikka, dyslipidemia, sydän- ja verisuonitauti, 
lihavuus, USF1, insuliiniresistenssi, FCHL, hypoalfalipoproteinemia 
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INTRODUCTION 
 
Coronary heart disease (CHD) is the leading cause of death in the Western world 
and increasingly so in the developing world as it adopts the progressively more 
sedentary lifestyle and dietary habits of the West. Dyslipidemia refers to an 
abnormal amount of various lipids in the blood and leads to the development of 
atherosclerosis -the root cause of this CHD epidemic. A host of enzymes, carrier 
proteins and receptors are involved in the careful regulation of lipid metabolism and 
a perturbation of any of these parts can potentially lead to the development of 
dyslipidemia and CHD. A number of familial forms of dyslipidemia exist, but in 
adults the acquired dyslipidemia associated with obesity is most common. 
Familial combined hyperlipidemia (FCHL) and familial low-HDL are two common 
hereditary dyslipidemias that both predispose to the development of premature (age 
<55 years for men, <65 years for women) CHD. Both are recognized to be complex 
diseases –that is the disease phenotype arises through the collective action of 
numerous genes and the environment. The presence of multiple predisposing genes, 
each increasing the disease risk only marginally, makes their identification 
challenging. Considerable efforts are currently being invested in the search for these 
genes and in characterizing the effects of the identified variants. Compared with the 
success at studying Mendelian, single-gene diseases, studies of complex disease are 
only recently being met with some degree of success. Complex diseases such as 
common dyslipidemias affect orders of magnitude more people globally than the 
rare, though generally more serious single-gene diseases. As such, these studies hold 
great potential for the improvement of human health –a selling point used to justify 
the enormous financial commitment that was the Human Genome Project. The first 
clinical applications of these findings are keenly awaited. 
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REVIEW OF THE LITERATURE 
 
1. Genetics of complex/common disease 
 
1.1 From descriptive genetics to functional genomics 
 
Through the contributions of such scientists as Gregor Mendel, James Watson, 
Francis Crick, Rosalind Franklin and countless other investigators, the study of 
heredity has been transformed from a purely descriptive endeavor to an 
understanding of the phenotype at the molecular level. The discovery of the 
structure of DNA actually predated that of the correct number of human 
chromosomes1, but it was the observation of chromosomal rearrangements that 
yielded the first described disease associated changes in the genetic material. Early 
work, employing the laborious positional cloning strategy in families with affected 
individuals, resulted in the discovery in 1989 of the first gene associated with a 
hereditary disease.  Cystic fibrosis was shown to be caused by mutations in a gene 
coding for a chloride ion channel, aptly named the cystic fibrosis transmembrane 
conductance regulator (CTFR)2,3. 
 
Since this first disease gene discovery, the molecular understanding of traits that 
follow Mendelian rules of inheritance in families –and thus referred to as 
“Mendelian diseases” has proceeded with leaps and bounds –greatly aided by the 
tools provided by the human genome project. To date, the gene behind more than 
2,200 Mendelian diseases has been identified (OMIM), whereas the progress in 
complex diseases that involve a number of genes, gene-gene and gene-environment 
interactions, has been much more modest (Figure 1). It is surely not for a lack of 
effort that so few reproducible complex disease gene findings have been reported, 
but rather it is the nature of the diseases and traits under study that make the hunt for 
these genes much more challenging. With more genes influencing the susceptibility 
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to disease, and this risk being modified by the environment, each genetic variant is 
likely to confer a smaller risk and thus be harder to detect. Complex diseases are 
also typically late-onset in nature, while monogenic diseases tend to be more severe 
and have an early onset (Figure 2). The difference between the two isn’t always 
clear cut, as there exist examples of families that seem to be segregating a complex 
disease in a near-Mendelian fashion. Studies of such exceptional families have 
revealed genes, and importantly pathways, that also play a role in the development 
of complex disease4. 
 
Despite the sluggish beginnings, the past few years have been marked however with 
an increasing number of reproducible complex disease gene findings, representing 
the latest revolution in our understanding of human genetics (Figure 3). These new 
association studies are characterized by very large study samples of cases and 
controls (tens of thousands of individuals), the employment of new technologies that 
enable investigators to interrogate up to a million common genetic variants in a 
single experiment and the use of expression arrays that enable the precise 
measurement of the transcriptional activity of all genes.  This has required the 
development of better statistical and analytical methods to mine the enormous 
amount of data generated. This thesis work has been carried out during this 
tumultuous time in the field of human genetics and includes a number of methods 
applying the modern technologies of molecular genetics. 
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Figure 1. Accelerating pace of gene discovery. In comparison to the progress 
made with Mendelian, single-gene diseases, complex disease gene identification has 
been orders of magnitude more modest. Adapted from5. 
 
Perhaps telling of our growing understanding of human genetics is the fact that even 
the so-called single-gene diseases are no longer considered to be such clear cut 
cases: while mutations in single genes are known to cause disease, numerous other 
genes can modify the phenotype (as is the case with cystic fibrosis)6, this raising the 
question whether any disease is truly a single-gene disease. What is being revealed 
is an enormous network of genetic interactions and pathways, orders of magnitude 
more complex than may have been assumed in the early days of genetics. It is the 
concern of functional genomics to ascribe meaning to the dynamic aspects of gene 
functions and interactions. 
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Figure 2. Development of a common/complex disease. The progression of a 
complex disease represents a continuum from health to pathology that develops over 
a long period of time. The diseases are thus typically late-onset and the outcomes 
(ex. myocardial infarct or stroke) are largely stochastic in nature. 
 
 
 
 
Figure 3. Pace of gene discovery for common diseases. With the advent of new 
technologies and truly massive study samples, the number of genes underlying 
common disease traits is beginning to gain momentum. Modified from a slide by Dr. 
David Altshuler. 
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1.2 The Human Genome Project 
 
For the most part of the late 20th century, the identification of genes and their 
assignment onto the map of human chromosomes was a time-consuming task that 
would take for a committed group of researchers years to complete. It was 
recognized very early that it would be of paramount importance for the scientific 
community to have the complete sequence of the human genome available and to 
assign a position on this map for every human gene. The Human Genome Project 
(HGP) was formally initiated in October 1990 with the stated goal of identifying all 
the genes in human DNA, to determine the sequence of the 3 billion chemical base 
pairs that make up human DNA and to make this information publicly available in 
databases. The project was also to improve tools for data analysis and to address the 
ethical, legal and social issues that may arise. The project was completed faster than 
anticipated with the first “working draft” of the human genome announced in the 
year 2000 and an essentially complete sequence finished in 2003 –precisely 50 years 
after Watson and Crick published their seminal paper on the discovery of the 
structure of DNA7 (Figure 4). 
The HGP has succeeded in its goals and is the foundation of all research in the 
modern field of human genetics. Much like the space race of the 1950s -70s drove 
technological advancements in aerospace engineering and electronic 
communication, the HGP, along with the race between the public8 and private9 
efforts as considerably improved and appended the genetic toolkit. The project has 
revealed the size of the human genome to be 3164.7 million nucleotides long and to 
contain an estimated 20,000-25,000 genes (HGP information web site).  The true 
number of genes may yet drop some from these estimates as more research is done 
and our definitions of what constitutes a gene change. This is a considerably lower 
number of genes than previous estimates of about 100,000 genes, based on 
extrapolations from gene-rich regions of the genome. 
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Figure 4. The structure of DNA and its packing into chromosomes in the cell 
nucleus. The entire length (about 3 meters) of DNA that makes up the human 
genome is tightly packed and organized into 23 pairs of chromosomes contained in 
the nucleus of the cell. (www.genome.gov/glossary.cfm) 
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 Less than 2% of the genome codes for proteins, while the considerable majority is 
composed of non-coding, inter-genic- and repeating sequences.  Some of these 
sequences, previously described as “junk-DNA”, on closer inspection have been 
shown to be functionally relevant10 and highly conserved –as has been learned from 
the comparison of sequence reads from the large number of other concurrent 
genome projects aimed at describing the full sequences of genomes of other 
species11. These comparisons have also revealed how closely related we are 
genetically to other species. These inter-species comparisons that can facilitate the 
identification of functional non-coding DNA elements in our genome are an 
essential tool in the study of complex disease, as a majority of the complex disease 
variants identified are located in these non-coding regions of our genome that 
presumably are involved in the regulation of gene expression5. 
 
1.3 Cataloguing the variation in the human genome 
 
1.3.1 Types of sequence variation 
 
With the exception of identical twins (excluding somatic mutations), no two 
individuals share the same precise sequence of nucleotides that makes up our 
genome. There exists variation in the sequence, and this variation is what in large 
part makes all individuals different. The genetic variation that exists in the human 
genome is present in several forms. The simplest and most abundant form of 
variation are changes in a single nucleotide of the genetic code.  These single 
nucleotide polymorphisms (SNPs), can be roughly divided depending on their 
location in relation to genes to those that are found within the protein coding 
sequences of genes and those that are not.  Further subdivision in the coding 
sequence SNPs can be made into those that either change an amino acid (non-
synonymous SNPs) and those that cause no change (synonymous SNPs), thanks to 
the redundancy in the genetic code. A SNP may also introduce a STOP codon into 
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the coding sequence, thereby causing the production of a truncated protein that most 
often has lost its function. Most polymorphisms are selectively neutral, but some 
carry functional significance. 
Another form of variation is simple deletion or insertion of a single (or a few) 
nucleotide(s). There can also be variation in the repeat number of a motif (mini- and 
micro-satellites). These motifs –composed of a repeating sequence of nucleotides, 
are prone to copying errors by the DNA replication machinery. This produces 
considerable variation in the number of repeats and this high degree of 
polymorphism is useful in genetic mapping. The vast number of polymorphisms 
identified, and subsequent accurate positioning of these markers along the 
chromosomal DNA strands have since the early years of the HGP provided us with a 
“handle” on individual segments of otherwise monotonously identical DNA between 
individuals. This ability, via these genetic markers, to discriminate between 
segments of DNA between maternal/paternal chromosomes and individuals enables 
the observation of their segregation in families and distribution in different 
populations –the basis for disease gene identification. 
 
1.3.2 The HapMap project 
 
Building on the work of the Human Genome Project that described the complete 
sequence of the human genome, the HapMap project was undertaken to catalogue all 
the common patterns of variation in the code. An estimated 10 million SNPs (with 
minor allele frequency >1%) exist in human populations. These SNPs are not 
inherited entirely independently of one another, but rather in more or less distinct 
blocks, with SNPs located in close proximity tending to be inherited together. This 
“non-random association of alleles at two or more loci” is termed linkage 
disequilibrium (LD). The pattern of LD is a result of the various forces of selection 
that have molded the human genome during the history of our species. 
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It was the proposition of the HapMap project that in order to describe the majority of 
the allelic diversity in a sample, it may not be necessary to genotype every variant. 
Rather, it may suffice to genotype only a subset of common SNPs (defined as 
having a frequency 5%) that “tag” a certain DNA segment carrying a number of 
markers in LD –a haplotype12. This greatly reduces the amount of genotyping 
needed to describe common variation in the genome, which directly translates to 
reduced cost of such studies12.  
The utility of the HapMap to aid in the identifying of disease variants rests on the 
assumptions behind the common disease common variant (CD-CV) hypothesis. In 
short the theory suggests that many common diseases, such as type 2 diabetes 
(T2D), asthma, obesity, Alzheimer’s disease, psychiatric diseases and hypertension 
may be caused by a small number of common alleles. More correctly, that multiple 
common variants may confer susceptibility to these common diseases. Opponents of 
the CD-CV hypothesis argue however, that common diseases are caused not by a 
few common variants, but rather by multiple rare mutations, thus perhaps making 
the HapMap approach of only monitoring for common variants a futile affair13,14. 
With the first reports from massive genome-wide association studies (that rely on 
the HapMap as a reference) revealing multiple, replicable common disease gene 
findings, the starkest opponents may be losing ground. Here too the likely 
representation of true-biology probably lies somewhere between the two opposing 
views. Both common variants, as well as multiple rare variants contribute to the 
susceptibility to common diseases15-17, with the HapMap approach proving to be 
powerful in detecting the prior, while the latter variants may only be detectable 
through large scale re-sequencing efforts. The rare variants as well as the “grey 
zone”, the not so common, not so rare variants, behind common diseases and traits 
can potentially be identified by analyzing exceptional populations that due to their 
population history, exhibit an enrichment of rare alleles. 
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1.4 Genome-wide analyses of DNA 
 
1.4.1 Linkage analysis 
 
Most disease genes identified so far have been initially positioned in the genome via 
linkage analyses in exceptional families with multiple affected cases. The basis of 
linkage approach relies on the basic concept that in sexually reproducing animals 
such as humans, genetic diversity is generated in the process of meiosis through the 
formation of the male and female germ cells that recombine in fertilization to 
produce a new individual. Through the process of crossing over, a pair of 
homologous chromosomes exchanges segments, so that the resulting chromosomes 
contain segments from both of the original pairs. This crossing over takes place at 
least once on each chromosomal arm and the likelihood that two loci on the same 
chromosome are separated by a recombination event is related to their distance from 
each other. Loci on different chromosomes segregate independently and are thus 
said to have a recombination fraction (denoted by ) of 0.50. Loci right next to one 
another may never be observed to be separated by a recombination and thus have a 
recombination fraction of  =0. The recombination fraction thus ranges from zero 
(for complete linkage) to ½ (no linkage). It is the objective of linkage analysis to 
estimate this recombination fraction and to test whether this differs significantly 
from the null hypothesis of no linkage, i.e.  =0.50.  
The estimate of the recombination fraction is based on counting the number of 
observed recombinant individuals in a pedigree. However, in real-world pedigrees 
this may not always be possible to do in absolute terms and the test for linkage takes 
on a probabilistic expression –a likelihood ratio. The likelihood of linkage is 
compared to the likelihood of no linkage. By convention, this is typically expressed 
as a (base 10) logarithm of the ratio of these two likelihoods. This is called the 
logarithm of odds (LOD) score (Z). 
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The calculation of this LOD score over a range of different values of  and the value 
of  at which the LOD score peaks is considered to represent the most likely 
recombination fraction, and thus the genetic distance between the two loci. In an 
attempt to identify disease genes, this test is done between genetic markers and 
disease status. Manual calculation of LOD scores can be done for simple pedigrees 
and disease states, but in large pedigrees and with diseases with unusual inheritance 
patterns this calculation must be done using one of several computer programs 
specially designed for these calculations. A LOD score of 3 translates to an odds 
ratio of 1000:1 and this has traditionally been considered a statistically significant 
demonstration of linkage, where as a LOD score of -2 is generally accepted to 
demonstrate the exclusion of linkage18. 
 
1.4.2 Association analysis 
 
While linkage is a specific genetic relationship between loci in a pedigree, 
association in principle is merely a statistical statement about the co-occurrence of 
certain alleles with each other, or with a phenotype. Rarely however, do 
investigators have the luxury, or luck of directly testing the functional variant, but 
rather variants that are in proximity of the functional variant, and thus in linkage 
disequilibrium (LD) with it. This existence of LD between markers that are located 
close to each other is a demonstration of the fact that we are all in essence a part of 
an enormous pedigree of an unknown structure. Association studies that look for 
association between markers and disease status are in essence testing the bottom 
layer of this enormous pedigree where individuals with the same disease are 
assumed to also share nearby genetic markers, because they have inherited them 
from a distant, common ancestor (Figure 5). 
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Figure 5. An extended Schitzophrenia pedigree from the Finnish isolate. 
Association studies in a population sample assume that affected individuals (black) 
share disease alleles passed down from a distant common ancestor. Only affected 
probands and ascendants needed to connect them in a pedigree are shown (other 
connections likely exist). Figure provided by Dr. Teppo Varilo. 
 
Association analyses with a dense set of SNPs is the current gold standard when fine 
mapping a chromosomal region identified in a linkage scan utilizing hundreds of 
multiallelic microsatellite markers. Care must be exercised when designing and 
interpreting results from association studies, for not all observed associations are 
caused by linkage disequilibrium with a functional polymorphism. Spurious 
association can arise for several reasons, among them population stratification (the 
population under study consists of several genetically distinct subsets, each with their 
distinct allele frequencies), natural selection (two alleles may be associated because 
the are compatible with life only when inherited together) and simple statistical 
artifact19 –an increasingly relevant worry, with the enormous number of markers, and 
thus tests performed, in the new genome-wide association studies. Some of the 
features of the etiology and study of complex disease are described in figure 6. 
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Figure 6. Schematic model of the genetic study of complex disease. This figure 
highlights the etiology of a complex trait, or disease, and some of the issues 
complicating its study via genetic means. An observed phenotype is shaped by the 
environment, gene-environment and gene-gene interactions. With more genes 
affecting the phenotype, each individual gene is likely to have a smaller effect size –
making them more difficult to identify. Other confounding effects are introduced by 
our inept ability to precisely measure (and define) the phenotype, as well as the fact 
that more often than not, we are not testing the functional variant directly, but rather 
a marker in varying degrees of LD with it. 
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1.4.3    Combining the power of linkage and association 
 
As alluded to above, linkage produces association within families, but not among 
unrelated people. The situation changes however, when two individuals sharing a 
certain trait or disease phenotype also share the same segment of DNA related to this 
trait -passed down from a distant common ancestor. In such cases the individuals are 
said to share the segment identical by descent (IBD) because it originated from the 
same allele in an earlier generation. This is in contrast to sharing an identical 
segment of DNA, without having inherited it from a common ancestor, but rather 
via a separate mutation –a condition known as identical by state (IBS). The length of 
the shared segment between individuals is related to the time (number of meioses) 
since the last common ancestor, as well as to the population history. A population 
which was founded by only a handful of individuals and has experienced a recent 
expansion in size is characterized by enrichment, by chance, of rare alleles (founder 
effect) as well as by LD blocks that are longer than observed in a more outbred 
population with a historically more constant population size (Figure 7). 
Finland represents such a population isolate and consequently shows significantly 
less genetic diversity than most other Caucasian populations (Figure 8). In addition 
to relative genetic homogeneity, considerable environmental and cultural 
homogeneity reduce the confounding factors that hamper genetic studies in more 
outbred, mixed populations. The availability of good genealogical records and equal, 
high-quality national healthcare with detailed registries are another important reason 
genetic studies in the Finnish population have been so successful at identifying 
Mendelian disease genes. With the unique population history and genetic makeup, 
come a unique set of enriched diseases. A total of 36 rare, monogenic diseases have 
been enriched in the Finnish population and genetic studies have been able to locate 
the disease gene and mutation in 35 of these20,21. The genetic defect remains to be 
identified for PEHO, a form of infantile progressive encephalopathy22. 
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Figure 7. Development of Finnish population size. One quality of a population 
isolate that contributes toward an increased amount of LD is a relatively recent 
expansion of population size. Another characteristic is the presence of a number of 
population bottle-necks, small examples of which can be identified; Finland’s war 
(1808-1809) and the Great Famine (1866-1868). Modified from Statistics Finland. 
 
Studies in isolated populations have been very successful in mapping Mendelian 
disease-genes, but their utility in mapping complex-disease genes has been 
questioned. Several examples already exist however, where a disease gene identified 
in a population isolate among exceptional families with multiple affected individuals 
is upon further study revealed to be associated with an increased risk for disease in 
the general population as well as in more heterogenous populations4. Some 
informative examples include maturity onset diabetes of the young (MODY), 
familial combined hyperlipidemia (FCHL), familial Altzheimer’s disease as well as 
rare forms of epilepsies and migraine4. 
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Figure 8. Length of LD map across various populations. Considerable 
differences in LD map length across populations. The length of the LD map in LDU 
(as defined in23) in 12 different population samples is depicted in order of decreasing 
map length. AZO: Azores; CAU: outbred European-derived sample; SAF: 
Afrikaner; NFL: Newfoundland; SAR: province of Nuoro in Sardinia; ASH: 
Ashkenazi; ERF: a village in southwestern Netherlands; FIP: Finland nationwide; 
ANT: Antioquia; CR: Central Colombia; FIC: early-settlement Finland; FIK: 
Finnish subisolate of Kuusamo. Adapted from24. 
 
 
1.5 Analyses of mRNA and the transcriptome 
 
1.5.1     Expression analyses 
 
The central dogma of molecular biology, as it is known, states that information 
flows from DNA to RNA to protein. Stated simply, DNA contains the encoded 
instructions for making the various proteins that largely make up our bodies and are 
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responsible for catalyzing the chemical reactions that sustain life. DNA specifies the 
synthesis of a messenger RNA (mRNA) that after being edited in the nucleus, takes 
this information into the cytoplasm of the cell where the code is read by the 
ribosomes and translated to a specific sequence of amino acids. These chains of 
amino acids fold in a unique manner to form functional proteins (Figure 9). This 
flow of information from DNA to RNA to protein is essentially a one-way process 
(with the exception of retro-viruses like HIV that are capable of turning their RNA 
genome to DNA that then incorporates into the host genome.) 
 
 
Figure 9. Simplified schematic of the process of protein synthesis. A strand of 
DNA encoding a protein is read and a messenger RNA (mRNA) is produced in the 
process of transcription. After splicing of introns and some additional modifications, 
the mRNA moves into the cytosol and the triplet code of nucleotides is read by the 
ribosomes. In this process of translation a polypeptide chain of amino acids is 
produced which then is folded in a unique manner to form a functional protein. 
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Of the estimated 20,000-25,000 genes that make up our genome, only a fraction are 
“turned on”, or expressed in a given tissue at a given time. A quite different set of 
genes are expressed, and thus proteins made, in the different tissues that make up 
our bodies. Different diseased tissues also have their own expression “signature” 
compared to that of healthy tissues and detecting this signature can be important, 
because it can help to identify different subtypes of disease, such as different 
cancers, that respond to different treatments. Similarly, genetic diseases have their 
own specific expression profiles, that range from the total loss of a certain gene 
product (as is the case in many severe, early onset Mendelian diseases), to only a 
subtle change in the expression of a handful of genes, or a given biological pathway 
–as is suggested to be the case with most complex, late-onset diseases.  
The temporal and spatial expression of genes is under complex control that takes 
place at multiple different levels: binding of tissue-specific transcription factors or 
hormones to cis-acting elements of DNA influence the transcription of the gene, as 
do the so-called epigenetic changes that are only beginning to be understood. As the 
name implies, epigenetic modification takes place outside, or “on top” of the DNA 
sequence, perhaps most well described in the form of   methylation that can silence 
genes. Importantly, while these epigenetic modifications do not involve changes in 
DNA sequence, they present as mitotically and/or meiotically heritable changes in 
gene function25. These epigenetic changes seem to be in principle stable, but 
potentially affected by the environment. This raises the intriguing notion with an 
admittedly Lamarckian ring to it, that acquired changes may be in part passed down 
from parents to offspring26.  Post-transcriptional regulation operates at the level of 
RNA processing, transport, stability and translation. In maintaining the proper 
expression of genes both temporally and spatially, the silencing of genes is just as 
important as the “turning on” of genes. New insights have relatively recently been 
gained to how this process takes place. MicroRNAs (miRNA) are short (21-23 
nucleotides), non-coding single stranded RNA molecules that are partially 
complementary to specific mRNA molecules (their 3’ UTRs) and can thus bind to 
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them and inhibit their translation into proteins27. This can take place through either 
direct inhibition of translation or by triggering the degradation of the mRNA 
transcript through a process similar to RNA interference. These miRNAs have raised 
considerable interest as their important role in controlling gene expression is 
beginning to be appreciated. Hundreds of miRNAs are predicted to be present in 
higher eukaryotes28 and it is speculated that they may play a role in the 
pathogenesis, and in the future possibly in the treatment of numerous diseases29.  
Our ability to detect and accurately measure the global transcript profiles of 
biological samples has revolutionized genetics and provided a whole new “ –ome” 
to investigate; namely the transcriptome. Active genes are actively transcribed and 
can be detected through their abundant mRNAs. The expression level of a gene 
represents the phenotype closest to the gene and is thus in a sense a purer phenotype 
than some of the classical ones such as measures of plasma triglycerides (TG) or 
cholesterol. There exist however, many levels of regulation beyond that of gene 
expression, so that conclusions  made from transcript level changes alone must be 
made with the caveat that they may not be identically represented at the protein 
level. Expression profiles in essence provide investigators with a snap-shot of genes 
at the functional level.  
The simplest method of measuring a gene’s expression level is by reverse-
transcriptase PCR (RT-PCR), whereby the total mRNA extracted from a tissue is first 
turned to complementary DNA (cDNA) by the enzyme reverse transcriptase. The 
abundance of cDNA is then measured with specifically designed primers in a machine 
that is capable of quantitating the amount of product produced in a PCR reaction. A 
larger amount of starting template cDNA results in a larger amount of amplified 
product and the amount of cDNA is directly related to the activity of the gene. This 
method is popular because of the relatively low cost associated with running the 
experiments, but is tedious because the expression of genes can only be measured one-
by-one. New methods involving array technology with more than a million individuals 
probes printed onto special slides enable the detection and precise measurement of all 
 36
genes in a single experiment. This method produces an enormous amount of 
information, but is still relatively quite expensive to perform. The expression arrays 
used in this study are the Affymetrix U133 Plus 2.0 arrays that analyze the expression  
level of over 47,000 transcripts and variants, comprised of more than 54,000 probe 
sets and 1,300,000 distinct oligonucleotide features. While this platform enables the 
interrogation of all individual genes, it importantly enables the inspection of a 
collection of relevant inter-connected genes –a biological pathway. 
The expression profiles of individuals exhibit large differences, not only because of 
differences in environmental exposure, but also because of their unique genetic 
make-up. Polymorphisms in the promoters of genes, enhancer elements, in 
transcription factors, methylation sites, miRNAs and their binding sites all have the 
potential to effect the expression of genes. The majority of polymorphisms that 
underlie the different susceptibility to complex disease are thought to  be located in 
such sequences30-32. With the availability of genome-wide tools to analyze both all 
the common variation as well as the expression profiles of practically every gene in 
an individual, new and exciting possibilities have emerged from combining these 
two levels of genetic information. Using the expression levels of genes as 
quantitative phenotypes in linkage studies has recently enabled the identification of 
so-called expression quantitative trait loci (eQTLs) that contribute to phenotypic 
differences between individuals33.  
 
1.5.2     Extending the transcript analyses to biological pathways 
 
No man is an island and no gene acts in isolation, but rather as a part of a biological 
pathway with numerous potential interactions with other genes. Especially in the 
case of complex disease where the measured changes in expression of a particular 
“disease gene” are likely to be only modest, the detection of these changes can be 
not only challenging methodologically and statistically, but also of only limited 
utility. The even subtle perturbation however, of an entire biological pathway in a 
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disease state can be of much higher utility, not only because of its likely greater 
effect on the individual over time, but as it uncovers a whole host of potential new 
candidate genes, as well as druggable targets.  
The topography of a pathway can be viewed as a series of interconnected entities 
(genes, in this case) with central positions, or hubs, occupied by transcription factors 
and other proteins that have wide ranging effects on the expression of numerous 
other genes. Most familiar examples of biological pathways are the metabolic 
pathways, through which a given metabolite (for example glucose) is consecutively 
modified by a number of enzymes (for example the enzymes of glycolysis and the 
citric acid cycle), some of which are highly regulated and act as control points for 
the entire pathway. Other examples of pathways are signal transduction pathways 
and developmental pathways, all of which have different dynamics of operation and 
different regulatory characteristics.  
Most current characterizations of biological pathways are incomplete 
approximations of the multi-dimensional nature of the true biology, but a consortium 
of scientists has attempted to describe gene products in terms of their associated 
cellular processes, molecular functions and cellular components. The Gene 
Ontology Consortium has assigned each gene in their database to these three 
categories in a tree-like arrangement34. This cataloguing of gene products to 
associated processes not only attempts to bring consistency to gene descriptions, but 
also facilitates the extension of expression analyses to the level of a whole biological 
pathway –an important tool in the study of complex diseases. 
 
1.6 The concept of replication in the context of complex disease 
 
One challenge that has come about with the advent of massive genome-wide 
association studies is to separate true findings of association with a phenotype from 
the slur of false positives that are sure to appear with the large amount of tests being 
performed in each study. Replication of original findings in independent collections 
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of samples is necessary for establishing the validity of an association. There exists 
however, disagreement over what constitutes a true replication in the context of 
complex disease findings. Unlike the replication of monogenic disease linkage 
findings, reports of which filled genetics journals until of late, for true replication in 
the case of complex disease it is not sufficient to merely replicate the same 
chromosomal locus as the original report. But what standards should one set for 
accepting a replication as valid? Is it sufficient to find a similar association with a 
different marker in the same gene? How strong should the LD be with the marker of 
the original report? Can that marker be located outside the gene and if so, how far? 
Should it be a requirement that the associated allele is the same in all studies?  And 
concerning the phenotype; does the association have to be with the very same 
diagnostic endpoint as in the original finding, or can the association be with a 
component trait (or endophenotype) of the disease, or endpoint? 
Many issues should be considered in the design, execution and reporting of a 
replication study in order for the scientific community to be able to draw 
conclusions of the validity of the findings. Issues involving the study population as 
well as phenotypes and markers analyzed, all are possible confounders. While a 
replication in a population of different ancestry should increase the confidence in the 
validity of the finding, failure to replicate should not necessarily be considered to 
invalidate the original finding, owing to differences both in the important 
environmental factors, as well as possibly different haplotype structure in the locus 
under study. Ideally, the replication should be with the same marker, or one in 
perfect LD (r2=1.0) as the best result in the original report. However, since most 
initial reports do not claim to have identified the functional variant, testing and 
reporting on additional SNPs (even ones not tested initially) in the region should 
only aid in identifying the causal variant(s). Unfortunately, many reports of 
replication have been content at genotyping only the best associating variant(s) of 
the original study and thus the opportunity is lost for more finely dissecting the 
association signal. The importance of reporting negative results should also be 
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emphasized35,36. Publishing negative results is difficult, but disseminating such 
information may provide a crucial element in dissecting the effect of the proposed 
disease gene, as well as for aiding in making the decision of whether or not to 
pursue time consuming functional studies. 
 
1.7 Identifying functional variants 
 
In addition to competently performed replications of original findings, attaching 
functional significance to the identified polymorphisms holds great importance for the 
process of convincing the scientific community of the validity of a finding. Even more 
so in the case of complex disease genes, since the polymorphisms identified are 
generally more cryptic in nature and don’t immediately present any obvious defect.  
This is in contrast to most mutations identified for the more serious, early onset 
monogenic diseases where the mutations usually result in serious damage to the 
protein structure. Our comprehension of the relationship between non-coding variants, 
gene expression and effects on phenotype is considerably more limited than our 
understanding of changes in coding sequence and resultant effects on protein function.  
 
Functional variants for complex traits are more likely to be located in non-coding 
regions of the genome that affect transcription. Such variants that affect the 
transcription of the gene can be found in the promoter regions of the gene (that can 
be located several kilobases away, as is the case with the variant associated with 
adult type hypolactasia located nearly 14 kb upstream of the lactase gene)37 and 
enhancer elements located in introns. Mutations or polymorphisms in the promoter 
and enhancer elements can change the affinity of transcription factors for their 
cognate sequences and thus affect the transcription of the gene. Sequence changes in 
the untranslated regions (UTRs) may affect the stability of the mRNA prior to 
translation into protein. These sequence changes, in addition to possible differences 
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in methylation/acetylation states of DNA, can have effects on the level of expression 
of the gene under different circumstances.  
 
The presence of multiple, associated non-coding intragenic SNPs in high LD can 
make it difficult to prioritize SNPs for functional studies. Evaluating the inter-
species conservation of the surrounding sequence can help in this task, as evolution 
conserves function. Special softwares have been designed to assist in this task38. 
They take use of multiple between-species comparisons as well as knowledge over 
the binding sequences of transcription factors and can predict which variants have 
the highest likelihood of being functionally relevant. In the end however, 
functionality must be tested using actual laboratory experiments. Some of the more 
commonly used assays include testing the sequence for promoter activity in a 
reporter-gene construct in cell  lines, and testing for changes in DNA binding 
capability in electrophoretic mobility shift assays (EMSAs). The most conclusive 
evidence for the functionality of a variant is that the phenotype can be “rescued”, or 
changed by replacing the variant allele. Proving this may be difficult in an in vitro 
test lacking the correct physiological environment, necessitating the use of 
experimental animals. Finally, given that the physiologies of humans and 
experimental species are not identical, the ultimate evidence for the functional 
significance often uses combined strategies of reaching from cellular experiments to 
population studies and analyses across species. 
 
1.8 Extrapolation of complex disease findings 
 
Geneticists use the terms “complex disease” and “common disease” 
interchangeably. By definition, they affect a considerably larger portion of the 
population than the much rarer monogenic diseases. The ultimate goal of the study 
of disease genetics should be to eventually translate the findings to benefit human 
health. Findings in monogenic diseases have firstly enabled the precise molecular 
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diagnosis of disease and given the tools needed for genetic counseling of families -
exemplified by implementation of the molecular findings of the Finnish Disease 
Heritage (www.findis.org). Going from disease associated gene-identification to 
concrete health benefits in the context of common diseases is a much more 
challenging task, as the variants identified may only marginally increase the life-
time risk of developing disease. The very use of the term “risk” exemplifies a fact 
about complex disease findings; their relevancy may only be obvious at the level of 
populations and that individual risk is essentially impossible to predict. This feature 
suggests that the benefits to human health are less likely to come in the form of 
prevention or prediction. The identification of complex disease-associated genes and 
importantly with them, biological pathways related to the disease process, may open 
up a new druggable system. Benefits to human health may thus be more likely to 
come in the form of new drugs. Perhaps the most prescribed class of type 2 diabetes 
(T2D) drugs are the Thiazolidinediones  (ex. Rosiglitazone) that act to alleviate 
insulin resistance by binding to the transcription factor PPAR39 – a gene that has 
later been shown to associated strongly with T2D40. While in this case the drug 
discovery preceded the association of the gene with the disease, there is reasonable 
hope that similar gene discoveries will provide the new druggable targets that 
translate to considerable benefit to human health in the near future. 
 
1.9 The thrifty gene hypothesis 
 
The prevalence in the Western world of metabolic derangements such as obesity, 
type 2 diabetes and their sequelae has dramatically increased in the past decades to 
the point where medical professionals are using the term “epidemic” to describe the 
current situation. While it is generally accepted that obesity and T2D have a genetic 
component, our genes haven’t changed during the time that this epidemic has come 
about. What has changed is our environment. In 1962, James V. Neel introduced the 
thrifty gene hypothesis, suggesting that what is behind the current increase in 
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obesity and related conditions is the mismatch 
that arises from having “stone-age genes in a 
space-age environment”41. The overwhelming 
majority of human evolution took place in the 
hunter-gatherer environment of the 
Paleolithic, and we are not only evolved from 
these Paleolithic hunter-gatherers, genetically 
speaking we still are them. The hypothesis 
posits that the existence of our ancestors 
consisted of cycles of famine and feast, 
physical activity and rest. In the current 
world, our existence is more characterized by sustained feast and physical inactivity 
–the cycle has stalled. In such an environment, the thrifty genes that conferred a 
reproductive advantage to those individuals who could efficiently store energy (in 
the form of fat and glycogen) are now the very genes that confer greater 
susceptibility to the so-called life-style diseases. The suggested mechanism may be 
seen at work among the geographically isolated Pacific Islanders where it is 
suggested that thrifty genotypes have been selected for even more strongly because 
of the long and difficult overseas journey required by their ancestors to reach the 
remote islands42. Following the so called “coca-colonization” of these communities, 
some groups where no recorded diabetes existed 50 years earlier, now have the 
highest rates of T2D in the world with more than 40% of the population afflicted43.  
 
Some opponents of the hypothesis question the ability of periods of famine to exert a 
selection pressure intense enough for thrifty genes to become common in a 
population44. It is also argued that the majority of deaths at the time of famine are 
not caused by starvation per se, but rather through infection and diarrhea –perhaps 
brought about indirectly by the lack of food, but not malnutrition itself. Those most 
likely to succumb to a famine are the very young and elderly, while those 
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individuals in their reproductive prime are most likely to survive –a fact that has 
been used to argue that no strong selective pressure can be asserted by famine. 
These arguments however do not address the other factor in the equation, i.e. the 
cycle of physical activity and rest. No clear cases of thrifty genes have been reported 
yet, but absence of proof is not proof of absence. With an increasing number of 
common obesity and T2D susceptibility variants being identified, the thrifty gene 
remains an intriguing hypothesis. 
 
 
2. Common Dyslipidemias 
 
2.1 Familial combined hyperlipidemia 
 
2.1.1 History and diagnosis 
 
In 1973, three groups in Helsinki45, Seattle46 and New York47 independently 
described a new inherited disorder of lipid metabolism among young survivors of 
myocardial infarction. The disorder was named familial combined hyperlipidemia 
(FHCL) and the diagnosis consisted of a multiple types of dyslipidemia in the 
family: isolated high cholesterol (Fredrikson’s lipid phenotype IIA), isolated high 
triglycerides (IV) and the combined phenotype (IIB). In addition, elevated levels of 
apoB and low levels of HDL are also often observed among affected individuals. 
Another feature of the condition is that affected individuals may change their lipid 
phenotype between visits to the clinic. While it was originally suggested that FCHL 
may be a case of a variable expression of a single autosomal gene46 dominantly 
inherited, it is now clear that FCHL is a complex disease with multiple genes and 
environment affecting the phenotype. Clinical diagnosis relies on accurate 
population based, age- and sex-specific cut-off levels of lipid measurements. The 
presence of early coronary heart disease (CHD) in the family has been a requirement 
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for a diagnosis of FCHL in some studies. The cut-offs for plasma lipids have varied 
between different studies, resulting in variable diagnoses and encumbering the 
search for the molecular basis of the disease. Finnish studies use the 90th percentile 
in triglyceride and cholesterol measurements, appropriate for the population and 
individual, as the cut-off point to establish affection status (Figure 10). The 
population prevalence of FCHL is estimated to be 1-6%, making it the most 
common familial dyslipidemia predisposing to CHD46,48. The prevalence among 
patients with premature CHD is much higher, at approximately 20%46.  
 
 
Figure 10. An example of a typical Finnish FCHL family. Modified from the 
thesis of Päivi Pajukanta49. 
 
 
2.1.2 Metabolic disturbances 
 
The complex FCHL phenotype has been extensively dissected in an attempt to 
reveal the underlying metabolic disturbances. A primary defect in lipoprotein 
metabolism is the hypersecretion by the liver of apoB containing lipoproteins 
(VLDLs) as well as the delayed clearance from circulation of their atherogenic 
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remnants. This contributes to the elevated plasma triglycerides, apoB and total 
cholesterol. As would be expected of a multifactorial disease such as FCHL, 
involving a system as complex as lipid metabolism, it is difficult to discriminate 
between cause and effect in its etiology. The multiple different component traits of 
FHCL are listed in table 1. These quantitative traits are in themselves open to 
genetic analysis and may reveal causative- and modifying genes for FCHL.  
 
Table 1. Additional FCHL component traits 
Trait Reference 
HDL-C                                         50 
LPL activity                                 51 
Glucose tolerance                        52,53 
Insulin                                         54 
ApoB containing lipoproteins     55,56 
Small dense LDL particles          57,58 
Abdominal obesity                      59,60 
Free fatty acids                            61 
 
Patients with FCHL are often overweight and to a variable degree insulin resistant59. 
These are also key features of the metabolic syndrome and accordingly, it has been 
suggested that the two diseases share etiological overlap. Obesity can mimic the 
FCHL lipid phenotypes and has been shown to be a confounder in making the FCHL 
diagnosis. Obesity has therefore been an exclusion criterion in some studies and can 
also be considered to modify the FCHL phenotype59,62,63. A fuller understanding of 
the physiological changes that occur as a result of acquired obesity are thus also 
important for disentangling the genetic, versus environmental contributions to the 
FCHL phenotype.  
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2.2 Dyslipidemias with overlapping phenotypes 
 
2.2.1 Low-HDL 
 
The FCHL phenotype is a mixed dyslipidemia with several component traits. It 
therefore shares phenotypic overlap with several other disorders with narrower 
definition of dyslipidemia. One such CVD predisposing disorder is familial low 
HDL. High density lipoprotein (HDL) is responsible for the reverse transport of 
cholesterol. Through this process, HDL transports cholesterol from extrahepatic 
tissues to the liver for excretion in bile (Figure 11). There exists a clear inverse 
relationship between the levels of HDL-C and the risk of developing premature 
coronary heart disease64. A low level of HDL is in fact the most common 
dyslipidemic finding in patients with premature coronary heart disease65. Aside from 
its role in the reverse transport of cholesterol, HDL has important anti-inflammatory 
effects that protect against CVD66.   
 
Figure 11. Reverse transport of cholesterol.  CE: cholesteryl ester, FC: free 
cholesterol. (Modified from67) 
 
Mutations in several genes have been shown to cause rarer cases of familial low-
HDL, most notably in the gene encoding for ATP-binding cassette transporter A1 
(ABCA1) causing the rare Tangier’s disease68-70. ABCA1 facilitates the efflux of 
cholesterol from peripheral cells to lipid poor apolipoprotein A1 (APOA1) –the 
main apolipoprotein of the HDL particle. The virtual absence of HDL in Tangier 
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patients is associated with severe, early CVD. Mutations causing low-HDL have 
also been identified in other genes, among them important components and 
modifiers of the HDL particle; APOA171, lecithin:cholesterol acyltransferase 
(LCAT)72, and lipoprotein lipase (LPL)73,74. The most common forms of familial 
low-HDL however, are considered to be multifactorial and given the phenotypic 
overlap with FCHL, overlap in the genetic component to these two disorders most 
likely exists. In fact, variants in the gene encoding for apolipoprotein A5 (APOA5) 
have been associated with both low-HDL75, as well as with FCHL76-78. 
 
 
2.2.2 The metabolic syndrome 
 
The metabolic syndrome refers to a clustering of several metabolic risk factors in 
one person79. Not all physicians agree on the definition of the metabolic syndrome, 
perhaps appropriately also known as “syndrome-X.” According to the International 
Diabetes Federation consensus published in 2005, the diagnostic criteria for the 
metabolic syndrome are (for Europeans) a waist circumference 94cm (), 80cm 
() (indicating visceral fat accumulation) and at least two of the following: 
 
Table 2. Diagnostic criteria for the metabolic syndrome. 
Phenotype Diagnostic Criteria 
Serum triglycerides 1.70 mmol/l 
High-density lipoprotein (HDL) <1.03 mmol/l (),  <1.29 mmol/l () 
Blood pressure Systolic 130 mmHg, Diastolic 85 mmHg 
Fasting blood glucose 5.6 mmol/l 
 
The central defect (pun intended) in the metabolic syndrome is visceral obesity and 
the associated insulin resistance80.  The risk for type 2 diabetes is larger among 
individuals with the metabolic syndrome, than could be predicted from the 
individual risk factors alone. Just as with type 2 diabetes, the prevalence of the 
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metabolic syndrome has risen dramatically over the last decades and presents a 
tremendous burden on the health care system.  
 
2.2.3 Type II diabetes 
 
Also called diabetes mellitus type II and non insulin-dependent diabetes (NIDDM), 
type 2 diabetes (T2D) is a metabolic disorder very closely related to the metabolic 
syndrome. Both are characterized by insulin resistance and a relative inefficiency of 
the pancreas to secrete insulin. The dyslipidemia in T2D while similar to the 
metabolic syndrome, however, is more pronounced81. The age of onset for T2D is in 
general in adult age (although it is now also occurring in obese children) and the 
symptoms appear gradually, while the average age of diagnosis for  type 1 diabetes 
is 14 years and the symptoms are more severe and the onset is more rapid. Type 1 
diabetes results from the inability of the pancreatic 	-cells to produce insulin, while 
in T2D insulin production is usually normal, or even increased. 
 
Worldwide, T2D accounts for 90% of people with diabetes (WHO) and as the 
metabolic syndrome, is largely due to the increasingly sedentary lifestyle and 
obesity in the Western world. While environmental factors play the major role in the 
susceptibility to T2D, much research into the genetic component of the condition 
has also been done. Until now, not much progress has been made in uncovering 
these genes. Very few replicable findings have been made using the candidate gene, 
and positional cloning approaches, with exceptions being perhaps the genes 
PPAR40, CAPN1082 and KCNJ1183. However, very recent findings from unbiased, 
genome-wide association studies have revealed replicable association to a novel 
T2D gene; TCF7L284. This new finding represents some of the promise that is hoped 
from the study of complex disease genes; TCF7L2 is involved in the wnt-signalling 
pathway important for the development of the enteroendocrine system85. This 
pathway had not previously been considered to be potentially involved in T2D and 
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thus opens up a whole new, perhaps druggable, pathway and several interesting 
candidate genes. The best associating risk SNP variant in TCF7L2 confers a relative 
risk for developing T2D of 1.45 in heterozygotes and 2.41 in homozygotes –quite 
high for a complex disease variant84. Interestingly, the risk variant here is very 
common (with a frequency of 27.6% in the controls and 36.4% in the cases) perhaps 
suggesting that the variant had undergone positive selection in the past and may thus 
fit the thrifty gene hypothesis. In addition, variants in this gene have also been 
reported to be associated with the triglyceride component trait of FCHL86. 
 
 
2.3 Obesity and dyslipidemia 
 
Considering the enormous quantity of food ingested, and energy expended in a year, 
it is an amazing feat by the systems maintaining homeostasis in the human body that 
body weight remains essentially constant. Most fundamentally, obesity is the result 
of a misbalance between excessive energy intake and insufficient expenditure. Extra 
energy in the time of plenty is stored by the body to be used at a time of scarcity 
(that in today’s society seldom comes). Most of the energy storage is in the form of 
triglycerides in adipocytes and it is released from these depots as necessary. The 
amount of stored fat varies between individuals and a crude, but practical indicator 
of the amount of stored fat is the body mass index (BMI), which is the bodyweight 
in kilograms divided by the square of the 
height in meters. Values above 25 kg/m2 
are considered overweight and values 
above 30 kg/m2 obese. Considerable 
morbidity and mortality is associated with 
the extremes of BMI, as can be observed 
from the J-shaped graph of mortality 
versus BMI (Figure 12, left).  
 50
Obesity is a problem because of the complications that are associated with it –
among them atherosclerosis, hypertension and certain cancers. Important to the 
development of the morbidity associated with obesity is not only the amount of 
stored fat, but importantly where that fat is stored. Much more dangerous than 
subcutaneous fat, large amounts of visceral fat (that give some men the 
characteristic apple-shaped body) are associated with larger risk for disease87. Along 
with visceral obesity comes insulin resistance that can develop into type 2 diabetes. 
Dyslipidemic features that result from obesity are elevated levels of triglycerides, 
total cholesterol, free fatty acids and decreased levels of HDL –all atherogenic 
changes that predispose to coronary heart disease79. 
 
Adipose tissue is not merely the inert storage tissue that it was considered for a long 
time, but rather is now recognized as an important endocrine organ that actively 
produces hormones and cytokines that not only signal to the brain the amount of 
stored fat, but have profound impacts on the whole of human physiology. Leptin is 
the now classical adipose tissue derived hormone that acts as a lipostat, signaling to 
the satiety center in the hypothalamus to decrease food intake88. While considerable 
hope was initially placed on the potential of using exogenous leptin to treat obesity, 
no marked success has become of this approach. Rare cases of early-onset, very 
severe obesity are caused by inactivation of the leptin gene or its receptor89, but it 
doesn’t seem that common variation in the gene contributes to adiposity at the 
population level. Several other monogenic forms of obesity are known, but the 
search for common variants that affect BMI at the population level has only very 
recently reported success in identifying these common variants. Association of 
common variants in the FTO (fat mass and obesity associated) gene with obesity 
were recently reported by studies using the genome-wide association approach. 
Exemplifying the intimate relationship between obesity and T2D, the initial 
association was found for T2D, but upon closer inspection it was evident that the 
association with T2D was driven by the gene’s effect on BMI90. The role of this 
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gene behind common human obesity has since been replicated in multiple studies91-
96 and such, FTO represents the first well replicated gene behind common forms of 
obesity. 
It makes logical sense that some of the genes contributing to obesity would be 
expressed in the tissue most affected97. Genes involved in a number of processes 
taking place in adipocytes could potentially harbor genetic variation causing obesity. 
Some of these processes include adipogenesis,  lipid turnover, endocrine/autocrine 
functions as well as mitochondrial respiratory functions98 (Figure 13). The  
adipocyte mitochondria are only recently beginning to gain recognition as 
potentially very important factors in the development of obesity and insulin 
resistance99. 
 
Figure 13. Genes involved in the regulation of adipocyte maturation, function and 
hormonal signaling may be involved in the predisposition to obesity. Modified 
from98. 
 
 
2.4 Relation to severe cardiovascular disease 
 
Coronary heart disease is the major cause of death in the Western world today100. 
The significant role of cholesterol in the pathogenesis of atherosclerosis was first 
described by a Russian pathologist Nikolai Nikolajewitsch Anitschkow in a seminal 
paper in 1913. By feeding cholesterol to rabbits, he was able to induce vascular 
lesions closely resembling those found in humans. He described that these lesions 
contained cholesterol-laden foam-cells and speculated that the cholesterol was 
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entering the vessel wall from the blood. Nearly 100 years ago he famously stated 
that “there is no atherosclerosis without cholesterol”, but it took more than 30 years 
before serious research following up his findings got underway. Considerable 
controversy ensued over the role of elevated levels of serum cholesterol in the 
development and progression of atherosclerosis. From the current vantage point, 
where nearly everyone is aware of the “good” and “bad” cholesterol and even know 
their own levels, it can be hard to accept that as recently as the late 1980s there were 
still vocal critics of the cholesterol-atherosclerosis idea.  Since then an enormous 
body of epidemiological, pathological, genetic data and clinical observations has 
established dyslipidemias as independent risk factors for developing CHD101. 
 
The current understanding of the development of atherosclerotic lesions begins with 
excess LDL particles with their load of cholesterol, accumulating in the intimal layer 
of the artery wall. There they undergo chemical alterations and stimulate the 
endothelial wall to recruit monocytes from the circulation. These monocytes enter 
the vessel wall and mature there into macrophages that begin ingesting the excess 
LDL particles. Macrophages scavenging on the LDL particles become filled with 
these lipid droplets, taking on the appearance that gives them the name “foam-
cell”102. Other immune cells are also recruited into the lesion, bringing about the 
inflammatory response –now understood to be a key component in the development 
of the plaque103. Chemical messages, cytokines, secreted by the inflammatory 
components of the lesion induce the smooth muscle cells of the media to migrate 
and form a fibrous cap over the lesion. As the lesion progresses adluminally, it can 
slowly occlude blood flow to the tissues that it serves. When this occurs in the 
coronary arteries, the individual may be symptomless at rest, but during physical 
exercise when the demand for oxygenated blood rises sharply, the resultant tissue 
hypoxia is experienced as angina pectoris. A large plaque may rupture and the 
resulting hematoma can very quickly completely occlude the vessel, resulting in an 
 53
infarct (Figure 14). This same process, when occurring in the blood vessels that 
supply the brain, results in stroke. 
 
 
Figure 14. Progression of atherosclerosis. Accumulation of lipids and a 
recruitment of inflammatory cells into the intimal layer of arteries forms the lesions 
that are the hallmark of atherosclerosis. (Figure obtained from Wikimedia Commons 
/ Atherosclerosis.) 
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3. Genetics of familial combined hyperlipidemia 
 
3.1 Genetic loci identified and associated genes 
 
A whole host of enzymes, transporters, channels and receptors are involved in the 
careful control of lipid metabolism and it is in theory possible that a change in any 
one of these components can result in the sorts of dyslipidemia as are observed in 
FCHL. To date, three genome-wide scans have been performed in a non-biased 
attempt to identify genes underlying the complex FCHL genotype. The scans 
performed in the Finnish104, Dutch105 and British106 have identified several loci that 
likely harbor disease—associated genes. Three loci have been consistently 
replicated; 1q21-23, 11p and 16q22-24.1. In addition to genome-wide scans, 
multiple studies have evaluated the role of various candidate genes (Table 3). 
 
Table 3. Genes with reported involvement with FCHL. 
Gene Chromosome Type of Study References 
LPL 8p21.3 Family-based association 107 
LCAT 16q22.1 Linkage 108 
PPARA 22q13.31 Association 109 
TNFRSF1B 1p36.22 Linkage and association 110 
APOC3 11q23.3 Linkage, family-based association 111 
APOA5 11q23.3 Association 76-78,112,113 
HNF4A 20q13.12 Association 114 
LEPR 1p31.3 Association 115 
USF1 1q23.3 Linkage and association 116-120 
(Modified from Naukkarinen, Ehnholm and Peltonen 2006)121 
 
3.2 The 1q21-23 locus and dyslipidemia 
 
The initial genome scan done for FCHL in the Finnish population identified a strong 
linkage signal in the 1q21-q23 locus104. Interestingly, the same issue of Nature 
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Genetics also reported that a region syntenic to the human 1q21-23 locus was linked 
in a mouse model of combined hyperlipidemia122. This raised considerable interest, 
for if the same mutation was behind the combined hyperlipidemia phenotype in both 
human and mouse, it would significantly simplify the identification of the gene. The 
linkage of FCHL to this 1q21 locus was since replicated in German and Chinese-123, 
U.S. white-124 and Mexican125 FCHL families making it the best replicated FCHL 
locus. In addition, this region is also considered perhaps the best replicated T2D 
locus with convincing evidence of linkage in populations as diverse as Europeans126-
130, East-Asians131,132, Native-Americans133 and African-Americans (Steven C. 
Elbein, unpublished observation in134). 
 
 
4. Upstream transcription factor 1 (USF1) 
 
4.1 Association with FCHL 
 
In 2004, sequencing of regional candidate genes and fine mapping with SNPs led to 
the 1q21 locus yielding the first FCHL associated gene. Multiple non-coding SNPs 
in the gene encoding upstream transcription factor 1 (USF1) were both linked and 
associated with FCHL and many of its component traits in 60 extended Finnish 
FCHL families116. It was also found that the TXNIP gene –the human orthologue of 
the Hyplip1 gene shown to cause combined hyperlipidemia in the mouse, was not 
behind the disease in man. The strongest association was obtained with two SNPs in 
complete LD with eachother, located in the 3’UTR (rs3737787) and in intron 7 
(rs2073658) (Figure 15). The association signal extended into the neighboring F11R 
(also known as JAM1) gene, especially among high triglyceride men. Early 
functional evidence for the involvement of the intronic SNP rs2073658 was also 
presented, as a 60bp intronic sequence containing this variant had an effect on 
transcription in vitro in the forward orientation. No effect of the SNP variants on the 
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transcription of the USF1 gene itself could be identified in adipose tissue samples, 
but an overall effect on the transcript profiles could be identified. 
 
 
 
Figure 15. Schematic of the 6.7kb USF1 gene. SNPs genotyped in the original 
study implicating USF1 in FCHL are marked with numbers. Associated SNPs are 
identified with asterisks.116 
 
 
4.2 Central role in lipid- and glucose metabolism 
 
The carefully regulated control of genes involved in the metabolism of lipids and 
glucose is essential in effectively responding to different nutritional conditions 
brought upon by fasting/refeeding. USF1 occupies a central position in the 
transcriptional regulation of a number of genes involved in lipid and glucose 
metabolism (Table 4), as well as components of the inflammatory- and stress-
response. Together with a related transcription factor USF2 with which USF1 forms 
a functional heterodimer, they bind E-box sequences (CACGTG) in the promoters of 
their target genes and thus stimulate their transcription135,136. Perhaps the most 
important signal of changes in an individual’s nutritional status is insulin secreted by 
the pancreas in response to a consumed meal. The ability of the USF transcription 
factor complex to stimulate the transcription of their target genes is influenced by 
this insulin signal and it makes possible the intricate control of important insulin 
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responsive genes such as fatty acid synthase (FASN)137, acetyl-CoA carboxylase 
 
(ACACA)138 and apolipoprotein A5 (APOA5)139. 
USF1 is a ubiquitously expressed, evolutionarily conserved transcription factor of 
the basic helix-loop-helix leucine zipper family and has two known splicing variants 
140. The USF1 gene spans 6.7kb, has 11 exons and codes for 310 amino acids. 
Knock-out experiments in mice have established that while either of the USF genes 
can be absent and still produce a viable animal, USF1/USF2 double knock-out mice 
display an embryonic-lethal phenotype –highlighting their important role in 
development135. In line with the known function of USF1, knock-out mice lacking 
this gene displayed a severely delayed induction of the FASN gene by refeeding a 
carbohydrate-rich diet141. Considering the ubiquitous expression, wide-ranging 
effects and evolutionary conservation (99% conservation between human and 
mouse/rat at the protein level) it is perhaps no surprise that no coding variants have 
been identified in the USF1 gene. 
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Table 4.  Selected USF1 target genes 
Gene Symbol 
Apolipoprotein C3 APOC3 
Apolipoprotein A2 APOA2 
Apolipoprotein A5 APOA5 
Apolipoprotein E APOE 
Hormone sensitive lipase LIPE 
Fatty acid synthase FASN 
Spot 14 protein Spot-14 
Acetyl-CoA carboxylase alpha ACACA 
Acetyl-CoA carboxylase beta ACACB 
ATP-binding cassette, subfamily A1 ABCA1 
Osteopontin SPP1 
Renin REN 
Angiotensinogen AGT 
Glucokinase GCK 
Glucagon receptor GCGR 
Ghrelin GHRL 
Liver-type pyruvate kinase L-PK 
 
4.3 Role of USF1 in other lipid disorders and CVD  
 
Following the first report of USF1 association with FCHL and its component traits, 
a number of studies utilizing independently collected FCHL cohorts of different 
ethnic background attempted to replicate the association. Studies in Utah 
Caucasians117, Mexicans118 and Dutch119,120 FCHL families all reported significant 
association of USF1 SNPs with the FCHL phenotype. Given the known function of 
USF1, it represents an attractive candidate gene not just for FCHL, but for many 
other dyslipidemias and related conditions. Several studies have thus also evaluated 
the role of USF1 in data sets not ascertained for the FCHL phenotype120,134,142-149. It 
should be noted however, that two large scale studies ascertained for type 2 diabetes 
were not able to find evidence for the involvement of USF1 in the disease134,147 
suggesting that the 1q21 locus harbors multiple disease susceptibility variants that 
underlie the repeated linkage of this region to type 2 diabetes and USF1 may not 
alone explain the linkage. 
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AIMS OF THE PRESENT STUDY 
 
This thesis aimed at elucidating the molecular background of common 
dyslipidemias, such as FCHL and familial low-HDL by addressing the following 
specific aims: 
 
I. Identify the dyslipidemia predisposing gene(s) underlying the multiple 
reports of linkage to the 1q21 locus. 
II. Utilizing fat and muscle biopsies from patients, to elucidate the 
functional relevance of the variant(s) identified by correlating them 
with changes in global transcript profiles.  
III. To investigate the role of the previously identified dyslipidemia gene, 
ABCA1 in the pathogenesis of familial low-HDL by examining the 
reverse cholesterol transport process in patient and control samples. 
IV. Using a special monozygotic twin resource to address biological 
pathways of acquired obesity –a strong modifier/confounder of the 
dyslipidemia phenotype. 
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MATERIALS AND METHODS 
 
1. Study samples 
 
 
1.1 Dyslipidemic family collection 
 
The three first publications making up this thesis studied participants from large, 
multigenerational FCHL and low-HDL families collected as a part of the European 
Multicenter Study on Familial Dyslipidemias in patients with Premature Coronary 
Heart Disease (EUFAM)150, begun in 1995. These families were recruited in the 
Helsinki, Turku and Kuopio University Central Hospitals and the collection 
consisted of three phases. First, the probands were selected from among patients 
undergoing elective coronary angiography or from a registry of patients with 
confirmed myocardial infarction (MI). In the second phase the probands and their 1st 
degree relatives were examined to identify low-HDL and FCHL families, followed 
in the third phase by examination of all accessible relatives and spouses. From 
among these families, a total of 77 fat biopsies were used in the first two studies of 
this thesis (19 in study I, 58 in Study II). Study III utilized a total of 72 individuals 
that included low-HDL family subjects (28 affecteds and 19 healthy relatives) and 
25 healthy  control subjects.  All samples were collected in accordance with the 
Helsinki declaration and the ethics committees of the participating centers approved 
the study designs presented here. 
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1.2 FCHL families 
 
The inclusion criteria for collection of the FCHL probands were as follows: 
o Age 30-55 for males and 30-65 for females 
o  50% stenosis in one or more coronary arteries, or verified MI 
o Serum TC  90th age- and sex specific Finnish population 
percentile, or TG  90th percentile, or both. 
 
Exclusion criteria: 
o Type I diabetes mellitus 
o hepatic or renal disease 
o hypothyroidism 
o FH  
 
1.3 Low-HDL families 
 
The inclusion criteria for collection of the low-HDL probands were as follows: 
o Age 30-60 years 
o  50% stenosis in one or more coronary arteries, or verified MI 
o Serum HDL-C level below the 10th age- and sex specific Finnish 
population percentile 
o Additional lipid criteria: TC < 6.3 mmol/l in men and < 6.0 in 
women, TG < 2.3 mmol/l for both genders 
Exclusion criteria: 
o Type I or II diabetes mellitus 
o hepatic or renal disease 
o hypothyroidism 
o FH  
o BMI > 30 kg/m2 
 
 
The age- and sex specific Finnish population based cut-off values were based on the 
distribution of serum lipid values observed in the population survey FINRISK151,152 
and are listed below in table 5 for serum total cholesterol (TC) 90th percentile, 
triglycerides (TG) 90th percentile and high density lipoprotein (HDL) 10th percentile. 
All serum measurements are reported in mmol/l. 
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Table 5. Population-based cut-off values for various serum lipids in mmol/l. 
 
Age 
TC 
Men 
TC 
Women 
TG 
Men 
TG 
Women 
HDL 
Men 
HDL 
Women 
5-11 5.9 6.2 1.6 1.4 1.0 1.1 
12-14 6.0 5.8 1.7 1.6 1.0 1.1 
15-17 5.3 5.6 1.9 1.5 0.9 1.0 
18-20 5.9 6.0 2.0 1.7 0.9 1.1 
21-24 5.7 5.9 2.3 1.6 0.8 1.1 
25-29 6.2 6.1 2.4 1.7 0.9 1.1 
30-34 6.6 6.2 2.7 1.7 0.9 1.1 
35-39 7.0 6.4 2.9 1.8 0.9 1.1 
40-44 7.2 6.6 3.2 1.8 0.9 1.1 
45-49 7.4 6.8 3.4 1.9 0.9 1.1 
50-54 7.5 7.1 3.5 2.1 0.9 1.1 
55-59 7.5 7.3 3.5 2.3 0.9 1.1 
60- 7.4 7.6 3.5 2.5 0.9 1.1 
 
 
 
 
1.4 Twin samples 
 
1.4.1 Monozygotic twins discordant for BMI 
 
The participants in the fourth publication of this thesis work investigating the effects 
of acquired obesity were recruited from a population-based longitudinal study of 
five consecutive birth cohorts (1975-1979) of twins, their siblings and parents 
(N=2,453 families), identified through the national population registry of Finland153. 
Twin pairs included in the current study were enrolled based on their responses to 
questions on weight and height at age 23-27 years. From this cohort (Figure 16) the 
top 5% most obesity-discordant monozygotic twin pairs (one co-twin non-obese 
(BMI ∼25 kg/m2), and the other one obese (BMI ∼30 kg/m2)), with no significant 
height differences (<4 cm) were selected.   
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Figure 16. Between-twin correlation of BMI measurements. Figure provided by  
Dr. Kirsi Pietiläinen. 
 
Screening all MZ twin pairs (N=658) resulted in identification of 18 pairs above the 
95th percentile of BMI differences (3.1 kg/m2). Fourteen of these pairs (eight male 
and six female pairs) were willing to participate and thirteen pairs (eight male and 
five female pairs, BMI differences 3.3-10.0 kg/m2, height differences <3 cm) had 
adipose tissue samples available for the present study. All pairs were Caucasian, and 
their mean age was 25.8 (range 23.7-28.5) years. The subjects were healthy (based 
on medical history, clinical examination and structured psychiatric interview), 
normotensive and did not use any medications except contraceptives. Their weight 
had been stable for at least 3 months prior to the study. In addition, seven MZ twin 
pairs concordant for BMI (median BMI for Twin A 24.6 kg/m2 vs Twin B 25.4 
kg/m2) recruited from the same cohort were studied as controls in the mitochondrial 
copy-number analyses. 
 
1.4.2 Danish Twin Registry 
 
In the second publication, subjects for the muscle biopsy were identified through 
The Danish Twin Register and selected as previously described154,155. A total of 98 
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young (aged 25-32 years) and elderly (aged 58-66 years) twin pairs were included in 
the clinical examination. Both genotype and skeletal muscle USF1 mRNA 
expression levels were obtained from 71 of the twin pairs (58 younger monozygotic, 
32 younger dizygotic, 22 elderly monozygotic and 30 elderly dizygotic twins). 
 
2. Laboratory methods 
 
2.1 Table of methods used in the study 
 
Descriptions of methods used in this study can be found in the original publications 
accompanying this thesis, as described in Table 6. 
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Table 6. Materials and Methods used in this thesis study. 
Material or Method Original Publication 
 
Study samples  
FCHL families I, II 
Low-HDL families II, III 
Finnish MZ twins IV 
Danish MZ and DZ twins II 
 
Phenotyping methods  
Serum lipid measurements I-IV 
Euglycemic hyperinsulinemic clamp IV 
Dual energy X-ray absormetry (DEXA) IV 
Magnetic resonance imaging (MRI) IV 
Carotid artery ultrasonography III 
 
Laboratory methods  
DNA extraction I-IV 
Polymerase chain reaction (PCR) I-IV 
Agarose gel electrophoresis I-IV 
Quantitative real-time PCR II- IV 
Genotyping I-IV 
Sequencing II, IV 
Fat biopsies and RNA extraction I, II, IV 
Muscle biopsies and RNA extraction II 
Electrophoretic mobility shift assay (EMSA) I 
Enzyme linked immunoSorbent assay (ELISA) III, IV 
Liquid chromatography IV 
Macrophage cholesterol efflux assay III 
Proton spectroscopy IV 
 
Statistical methods  
Marker selection III 
Haplotype construction III 
Association analyses III 
Regression analysis III, IV 
Expression analyses I-IV 
Pathway analysis IV 
Permutation IV 
Correlation analysis I-IV 
Transcription factor binding site prediction II 
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RESULTS AND DISCUSSION 
 
1. Scanning the USF1 genomic landscape for a functional variant 
 
A previous study by our group identified four non-coding, intergenic SNPs associated 
with FCHL and its component traits in the USF1 gene located in chromosome 1q23.3. 
Typical of complex disease associated genes, none of the associated polymorphisms 
presented any obvious functional consequence that would explain the disease 
phenotype. Two variants in complete LD gave the strongest association signal and 
were thus considered the likeliest candidates for representing the functional 
polymorphism116. One is located in the 3’UTR (rs3737787 aka usf1s1) and the other in 
intron 7 (rs2073658 aka usf1s2). The complete LD made their prioritization by genetic 
means impossible and thus in study I, a comparative genetics approach was taken. The 
evolutionary conservation of all associating variants was evaluated by exploiting the 
sequence information of other species available at the time. Comparison of sequences 
surrounding the associating variants was made between human, chimp, dog, mouse, 
rat and chicken, revealing that the intron 7 SNP usf1s2 was located in a short patch of 
sequence conserved through all the species (Figure 17).  Interestingly, the variant 
nucleotide itself was conserved and the ancestral allele represents the associated risk-
allele. Sequence around the 3’UTR SNP usf1s1 was not itself conserved, despite being 
located in a transcribed region. 
 
The possible functional role of the sequence around variant usf1s2 in intron 7 was 
suggested already in the original work by our group reporting the association with 
FCHL, as a 268bp segment (including this variant) enhanced the transcription of a 
reporter gene in vitro116. Based on this and the observed conservation, it was 
possible that that the sequence contained an enhancer element and therefore in study 
I, the ability of the sequence to bind protein was tested in an electrophoretic mobility 
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shift assay (EMSA). Using two partially overlapping probes it was shown that the 
sequence immediately surrounding variant usf1s2 bound nuclear protein(s). 
 
Figure 17. Conservation of sequence around variant usf1s2. Comparison of 
sequence available from multiple species shows the strongest associating variant 
usf1s2 to be located in a conserved patch of sequence in intron 7 of USF1. All 
identified variants are indicated by numbers with the associated variants marked by 
asterisks. 
 
In the same issue of Nature Genetics as the original article by our group reporting 
the association of USF1 with FCHL116, a commentary by C. Shoulders suggested 
that an allele of the strongest associating SNP usf1s2 may activate an alternative 
promoter within USF1, resulting in the start of transcription from one of the two 
AUGs in exon 8 and thus a shorter protein product lacking the trans-activation 
domain156. This did not appear to explain the mechanism however, as in study I, 
USF1 transcripts of equal length were produced in individuals carrying either allele. 
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2. Effects of USF1 variants observed on numerous target genes 
 
A qualitative or quantitative functional change in a transcription factor would be 
expected to be reflected on the expression pattern of its target genes under 
appropriate conditions. It is through the altered transcription of the numerous USF1 
controlled lipid- and glucose metabolism related genes that the dyslipidemic 
phenotype associated with variants in USF1 is thought to arise. Our group also 
showed previously, first indications of this in a limited number of adipose tissue 
samples when an enrichment of lipid metabolism and immune response category 
genes differentially expressed in individuals carrying risk alleles (G) of usf1s2 was 
observed116.   
 
In order to determine the effect of different USF1 variants on the expression of known 
USF1 target genes, first in a collection of 19 fat biopsies (Study I), then in a larger set 
of 47 samples (Study II), known target genes were interrogated for differential 
expression in adipose tissue of individuals carrying different alleles of the disease 
associated SNP usf1s2. The two studies were carried out on different Affymetrix 
expression chips and thus had different number of genes detected. The second, larger 
study involving 47 fat biopsies were carried out on the newest U133 Plus 2.0 arrays 
and revealed that in a comparison of 24 carriers of usf1s2 risk allele (G) with 23 
individuals homozygous for the non-risk allele (A), 10 of the 31 known USF1 target 
genes expressed in adipose tissue were significantly differentially regulated (Table 7). 
Of interest was the observation that those genes that were upregulated were mainly 
ones involved with the immune- or inflammatory response and that genes involved 
intimately in lipid metabolism predominated the list of downregulated genes –findings 
that agree with the dyslipidemic, pro-atherogenic state. 
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Table 7. Differentially expressed USF1 target genes in adipose tissue. 
*P-value for non-parametric Mann-Whitney U-test 
 
While the list of known USF1 targets is growing, there are certainly many more yet 
to be identified. With the observed influence of the usf1s2 allele on the expression 
of known target genes, the global effect on gene expression in adipose tissue was 
evaluated in study II. To this end, first a list was generated of genes differentially 
expressed between the usf1s2 risk allele carriers and non-risk allele homozygotes. 
Of the 54,613 probes present, 30,155 passed initial filtering of the data set to 
exclude those genes with unreliably low signal intensity. Of this set, 4,847 probes 
(representing 3,693 unique gene products) were differentially expressed between the 
genotype groups (Welch t-test P<0.05). To test for the possible role of USF1 in 
controlling the expression of these genes, the oPOSSUM software was utilized38. 
This software combines a database of conserved transcription factor binding sites in 
human and mouse promoters with statistical methods in order to test whether the 
binding sites of certain transcription factors are over-represented in a given gene set. 
Of the 3,693 genes input, the software was able to analyze 2,897 and among this list 
of differentially expressed genes, binding sites for USF1 were significantly enriched 
(P=2.8x10-5). This implies a large-scale effect of the usf1s2 allele on the expression 
of numerous USF1 target genes that still remain to be identified. 
 
Gene 
Fold Change 
(risk/protective) 
 
P-value* 
FCER1A 1.48 0.006 
HLA-E 1.36 0.008 
PTPN6 1.30 0.027 
MAP2K1 1.24 0.007 
HOXB4 0.84 0.002 
THRSP 0.80 0.022 
ABCA1 0.77 0.003 
ACACB 0.68 1.6x10-4 
ACACA 0.53 0.001 
AGT 0.54 0.002 
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3. Functional defect exemplifies an interaction with environment 
 
Transcription factors control the expression of their target genes so that the 
functional proteins that they encode are appropriate in abundance, place and timing.  
When and where to activate transcription is in turn signaled by various 
environmental- and hormonal cues and for USF1 it has been shown that insulin is 
key in controlling the USFs post-transcriptionally139. Additional interest in the role 
of insulin in relation to USF1 was sparked by reports that carrier status of the usf1s2 
risk allele had been associated with a decrease in antilipolytic insulin sensitivity144 
and a poorer response to oral glucose- and fat tolerance tests149. 
 
In study II, the potential effect of insulin on the expression of the USF1 transcription 
factor itself was investigated in muscle biopsies from 142 Danish twins before and 
after a euglycemic hyperinsulinemic clamp. When analyzing all twins together, no 
change in the USF1 transcript levels could be detected, however a clear difference 
could be observed when dividing the subjects based on their carrier status of the 
usf1s2 risk allele. While no differences in the expression level of USF1 could be 
observed between the groups before the insulin administration, following the insulin 
challenge a dramatic increase in the transcript levels of USF1 took place in the 
individuals homozygous for the non-risk allele (P=0.004).  Those individuals 
carrying risk alleles of usf1s2 did not respond to the hyperinsulinemia (Figure 18). It 
seems that the risk-allele of USF1 is unresponsive to insulin at the transcriptional 
level, while non-risk allele carriers respond by up-regulating their USF1 expression. 
This provided the first allele-specific expression level difference in USF1 and to our 
knowledge for the first time showed this transcription factor to be regulated by 
insulin also at the transcriptional level.  
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Figure 18. USF1 mRNA following insulin clamp. In muscle biopsies analyzed 
before and after a euglycemic hyperinsulinemic clamp, individuals carrying the risk 
allele of variant usf1s2 failed to upregulate their USF1 transcript levels. 
 
In addition, it could be observed that men displayed significantly higher USF1 
mRNA levels compared to women (0.99 ± 0.06 [n = 71] vs. 0.72 ± 0.04 [n = 64], 
Pa= 0.002, and 1.0 ± 0.06 [n = 66] vs. 0.78 ± 0.05 [n = 59], Pa= 0.02, for basal and 
post-clamp USF1 mRNA levels, respectively). 
When one allele of a gene affects the expression of a gene, this may be detected in 
the heterozygous individual as allelic imbalance157 (Figure 19). This requires the 
capability to accurately quantitate the two different alleles in a heterozygous sample 
and can be done by various different means, among them by quantitative 
sequencing158. Even relatively small differences in transcript levels can be detected, 
owing to the design of the experiment where in a heterozygous individual the other 
allele can serve as an internal control. In the absence of pre- and post- insulin clamp 
fat biopsies ascertained on the usf1s2 genotype, eleven adipose tissue samples from 
individuals heterozygous for usf1s2 were assayed for allelic imbalance of USF1 by 
means of quantitative sequencing. Nine out of the eleven samples assayed exhibited 
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allelic imbalance of USF1 with the risk allele of usf1s2 being under-expressed by 
~20%. Importantly, there was a trend for higher imbalance (lower expression of the 
risk allele) with increasing levels of fasting serum insulin –as could be expected 
from the observation in muscle. Thus, in two relevant tissues the risk allele of USF1 
was expressed at a lower level compared to the non-risk allele and that this 
difference seemed to stem from an insensitivity of the risk allele to the inductive 
effect of insulin. 
 
 
Figure 19. Mechanisms that can result in allelic imbalance. Certain 
polymorphisms can affect the acetylation/methylation pattern of genes, or the 
recruitment of transcription factors and enhancers and thereby result in differential 
transcription of the two alleles. In a heterozygous individual this phenomenon is 
termed allelic imbalance (AI) and can be detected using various techniques. 
Modified from157. 
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The mounting data on the involvement of USF1 variants in predisposition to 
dyslipidemia (particularly high triglycerides) and heart disease in multiple different 
populations has convincingly made it the most well-replicated dyslipidemia gene 
identified by the positional cloning method. While the genome-wide association 
studies performed on cardiovascular traits so far have not reported USF1 among the 
top hits, its role in the pathogenesis of FCHL and related dyslipidemias especially in 
higher risk pedigrees is now well documented. The two strongest associating SNP 
variants of the original study have also been implicated in a majority of the 
subsequent reports, with the major allele of the variant rs2073658 associated 
increased susceptibility. Haplotypes carrying the minor allele of this variant 
however were deemed the risk variants in two population studies134,146 perhaps 
highlighting the complex interplay of environmental and additional genetic variants 
and the difficulty this introduces in the absolute determination of risk alleles. 
Sequencing in the original- and subsequent studies has failed to identify any new 
variants within USF1 that would present obvious functional potential and thus the 
results here described present the only functional evidence. While all the results 
point to the usf1s2 SNP being the functional polymorphism, the usf1s1 SNP located 
in the 3’UTR cannot conclusively be out-ruled, because of the complete LD between 
these two variants. It is also possible that polymorphisms within the neighboring 
F11R (a.k.a. JAM1) or close to it can contribute to the cardiovascular associations, 
given the fact that LD extends into this gene116 and it too has recently been 
implicated in CVD, as a gene over-expressed in atherosclerotic plaques159 and its 
levels in plasma associated with the severity of angiographically defined CAD160. 
Given the consistent linkage of this chromosomal region to T2D, yet the two 
negative reports on association134,147 with USF1, it is likely that multiple disease 
predisposing variants will ultimately be found in this chromosomal region, in the 
vicinity of USF1. The role of USF1 in lipid metabolism and in the molecular 
background of FCHL however remains unchallenged. The possibly different role of 
disease predisposing variants of USF1 in men and women warrant further 
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investigation since a significant interaction between gender and USF1 genotype was 
found in Dutch FCHL families and U.S. whites with CAD120 as well as among 
women in the prospective population cohort of Finns (Silander et al., submitted). 
The observed difference in the transcript levels of USF1 between the genders, as 
described here, may be involved. The overall incidence of CAD differs between men 
and women and surely there is a discordance in the battery of genes involved in the 
predisposition. 
 
In conclusion, variation within the gene encoding transcription factor 1 (USF1) 
predisposes to FCHL, other related dyslipidemias and cardiovascular disease. The 
functional defect seems to be a variant within the binding site of an enhancer 
element within intron 7 that is involved in regulating the expression of USF1 in 
response to insulin, as in a postprandial state. The transcript levels of USF1 in 
carriers of the risk allele fail to up-regulate in the hyperinsulinemic state and this is 
in turn reflected in a delayed response of numerous relevant target genes. With time 
these numerous small perturbations lead to the permanent changes that we see in 
individuals who develop dyslipidemia and heart disease (Figure 20). 
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Figure 20. Schematic representation of the suggested mechanism through 
which genetic variation in the USF1 gene predisposes to dyslipidemia and CVD.  
 
 
4. Variation within the ABCA1 gene and familial low-HDL 
 
Rare monogenic forms of low-HDL have been identified where a defect in the gene 
encoding ATP-binding cassette, subfamily A1 (ABCA1) –another target gene of the 
USF1 transcription factor161,  causes a virtual absence of HDL-C in the plasma and a 
resultant accumulation of cholesteryl esters within cells68-70. In addition, it has been 
shown that up to 10% of people in the lowest HDL-C percentile are heterozygous 
for rare ABCA1 mutations162. The possible role of common ABCA1 variants in 
Finnish familial low-HDL was assessed in publication III of this thesis work. The 
role of ABCA1 variants was examined at the level of the gene (genetic association), 
mRNA transcript (expression in patient derived macrophage foam-cells), functional 
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capacity (macrophage efflux capability to lipid-poor apoA-I) as well as clinical 
phenotype (correlation to several lipid measurements and carotid artery intima-
media thickness). This study was carried out in a collection of affected family 
members and a control group including healthy volunteers and spouses with no 
CHD or lipid abnormalities.  
 
Of 15 genotyped intragenic ABCA1 SNPs, four variants displayed significantly 
different allele frequencies between the case and control groups with rare variants of 
three of them enriched in the low-HDL cases. Three of these variants were also 
directly associated with the levels of HDL-C (Table 8).  Carrier status of the most 
common haplotype constructed of the three variants associated with HDL-C (L158, 
R219K and T1427) correlated with its levels in a dose-dependent manner: mean 
HDL-C level of individuals with two copies being 1.30 mmol/l, one copy 1.06 
mmol/l, and no copies 0.85 mmol/l (P=0.025, Kruskal-Wallis test) (Figure 21). The 
likelihood of an individual belonging to the low HDL group when carrying either 0, 
1 or 2 copies of this allelic haplotype were 80, 48, and 30%, respectively.  
 
 
 
Figure 21. Dose dependent effect of the common ABCA1 haplotype on HDL-C 
levels in serum. Error bars represent ±95th % confidence interval. 
 77
Table 8. ABCA1 allele frequencies between 47 low-HDL family members (19 
unaffected and 28 affected subjects) and 25 control subjects, and their effect on 
cholesterol efflux, HDL-C and mean IMT in the pooled study sample (N=72). 
 
 
 
SNP 
 
AA 
residue 
Allele frequencies and P-
value in low HDL family 
members vs. controls 
 
HDL-C 
(P-value)† 
 
Mean IMT 
(P-value)‡ 
rs2472459 - n.s. n.s. n.s. 
rs2246293 - n.s. n.s. n.s. 
rs2515616 - n.s. n.s. n.s. 
rs1800978 - n.s. n.s. n.s. 
rs2740492 - n.s. n.s. n.s. 
rs3858075 - n.s. n.s. n.s. 
rs1929842 - n.s. n.s. n.s. 
rs2230805 L158 (0.45 vs 0.12) 0.004 0.009 n.s. 
rs2230806 R219K (0.40 vs 0.08) 0.005 0.007 n.s. 
rs2487037 - n.s. n.s. n.s. 
rs2297409 - (0.30 vs 0.04) 0.006 n.s. n.s. 
rs2066716 T1427 (0.11 vs 0.32) 0.053 0.003 n.s. 
rs2230808 R1587K n.s. n.s. n.s. 
rs2066881 - n.s. n.s. n.s. 
rs4149341 - n.s. n.s. 0.025 
Modified from163. 
 
In order to investigate the functional capacity of ABCA1 in patient samples, 
macrophages isolated from patients were loaded with acetyl-LDL to produce a foam 
cell model. These cells were then unloaded by incubating them with lipid-free apoA-
1 as a primary cholesterol acceptor. Only a marginal, yet statistically significant 
difference could be observed in the cholesterol efflux capacity between cells derived 
from patients when compared with cells originating from healthy control subjects. 
Patient derived macrophages exhibiting a lower cholesterol efflux capacity, when 
normalized to macrophage protein content (dpm in medium/μg cell protein/18h) 
(Figure 22). 
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Figure 22. ApoA-1 mediated cellular cholesterol efflux in 22 low-HDL subjects 
and 21 controls.  Error bars represent mean ± SEM. Modified from163. 
 
The transcript levels of the cholesterol transporters ABCA1 and ABCG1 are known 
to be up-regulated in response to cells becoming loaded with cholesterol and 
conversely to fall upon de-lipidation164,165 and this was also observed in the Finnish 
samples. In the loaded macrophages, a distinct difference was observed in the 
transcript levels of ABCA1, with higher transcript levels somewhat surprisingly 
observed in the low-HDL group than in the control group (P<0.001). In light of this 
clear difference in ABCA1 transcript levels, but only a marginal difference in efflux 
% to apoA-I, we next expressed efflux by cholesterol efflux to apoA-I ( %)/relative 
ABCA1 mRNA expression as a measure of the efflux efficiency of individual 
ABCA1 proteins. This ratio was significantly reduced in the low HDL group when 
compared to the controls (3.93±2.30 vs 7.85±2.14, P<0.001) (Figure 23). 
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Figure 23. Cholesterol efflux efficiency in low-HDL subjects (N=10) compared 
with control subjects (N=11). Bars show mean ± 95% CI. Modified from163. 
 
The genotyped variants were also assessed for association with efflux efficiency of 
the patient macrophages. The L158 variant that had been associated with HDL-C 
levels also exhibited association with lower cholesterol efflux.  Carriers of the rare 
alleles in L158 had decreased efflux (%) as compared to non-carriers in the whole 
study sample (4.6±1.0 vs 5.7±1.3, P=0.009). While evidently not the major defect 
behind low-HDL in these Finnish families, sub-optimal ABCA1 function contributes 
to the impaired reverse cholesterol transport process. The defect(s) resulting in low 
levels of HDL in these families may also be found in the acceptors of cholesterol 
and the several HDL modifying enzymes found in the circulation. As low-HDL is 
also considered a complex disease, the presence of multiple different defects, each 
with a small effect on the phenotype may be the likeliest scenario. 
 
 
5. Consequences of acquired obesity –a confounding trait for dyslipidemias 
 
As the single most common cause of dyslipidemia, understanding the physiological 
and molecular changes that occur in acquired obesity is of fundamental importance. 
Alongside the study of genetic predisposition to obesity and dyslipidemia, 
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describing these physiologic changes at the molecular level will aid in designing 
appropriate intervention strategies and treatments. In addition, the genetic- and 
physiologic studies complement each other: careful investigation of the acquired 
components of complex traits have the potential of exposing new pathways and 
candidate genes to evaluate in genetic studies and vise versa. Most studies on the 
effects of obesity have been hindered by the vast amount of environmental- and 
genetic variation inherent in human studies, so in study IV, a unique approach 
involving rare, monozygotic twins discordant for BMI was utilized to expose obesity 
induced changes in biological pathways in an identical genetic background. 
Fourteen pairs of monozygotic twins from the most discordant (5% extreme) in BMI 
in a national registry of 2,453 twin pairs were selected for analysis (Figure 10). In 
addition to well-documented changes in body morphology and dyslipidemia, a 
number of novel perturbations were observed in the obese co-twins. 
 
A global analysis of adipose tissue gene expression pathways (as described by the GO-
consortium) revealed that fat cells in an obese individual are not merely larger in size, 
but that a number of active, pathological processes are evident from the transcript 
profiles. An activation of inflammatory pathways predominated the list of up-
regulated pathways (Table 9) underscoring at a transcriptional level the fact that 
obesity in large part is an inflammatory condition of fat tissue. An activation of both 
the adaptive- and innate immune systems could be observed as well as an increased 
transcription of several cytokines (MCP-1, MCP-2, MIP--R, MIP-4, MIR-10) that 
play roles in the recruitment of monocytes to sites of injury and infection. The single 
most over-expressed (5.9-fold) gene in the obese co-twins was osteopontin (SPP1), 
another cytokine involved in macrophage recruitment and stimulation of T cell 
proliferation during inflammation166 and a known target gene of the USF1 
transcription factor167. In addition to the findings presented here, a very recent study 
on diet-induced obesity in mice also suggests that SPP1 may play a role in linking 
obesity to the development of insulin resistance by promoting inflammation and 
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accumulation of macrophages in adipose tissue168. Secretion of SPP1 was increased 
during obesity and unlike wild-type mice, animals lacking SPP1 were protected from 
developing insulin resistance despite the diet-induced obesity. While the adipocytes 
themselves were expressing an increasing amount of SPP1 in obesity, the increase in 
SPP1 mRNA in whole adipose tissues was in most part due to an increased of 
transcript levels in macrophages168. These results paint a picture where an increased 
degree of adipocity leads to secretion of SPP1 by the adipocyte, attracting 
macrophages from the circulation, which in turn begin secreting more SPP1 leading to 
an accelerating accumulation of adipose tissue macrophages. The presence of 
macrophages in adipose tissue has been shown to directly interfere with insulin 
signaling and insulin-stimulated glucose uptake in adipocytes by decreasing GLUT4 
and insulin receptor substrate 1 (IRS-1) expression169. Together with the concurrent 
report in the mouse model of diet-induced obesity, the novel observation in study IV 
of the dramatic increase of SPP1 expression in obese humans for the first time links 
this cytokine as an important player in the development of insulin resistance. Over-
expression of PPAR, or treatment with a thiazolidinedione has been shown to 
suppress SPP1 transcription170 and SPP1 deficient mice are protected from obesity 
associated insulin resistance168, raising the possibility that specific targeting of this 
secreted cytokine could present a novel treatment strategy for type 2 diabetes. 
 
Table 9. Top 10 most upregulated pathways in adipose tissue of obese-cotwins. 
Pathway Name Nominal P Empirical P* 
Antigen processing and presentation of exogenous 
antigen 
2.99E-11 0.0001 
Inflammatory response 1.16E-10 0.0001 
Humoral immune response 1.31E-10 0.0001 
Locomotory behaviour 1.00E-09 0.0001 
Immunoglobulin mediated immune response 1.06E-09 0.0001 
Actin cytoskeleton 3.30E-09 0.0001 
Antigen presentation 5.02E-09 0.0001 
Chemotaxis 1.26E-08 0.0001 
Taxis 1.26E-08 0.0001 
Cellular defense response 5.88E-07 0.0001 
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Table 10. Most down-regulated pathways in adipose tissue of obese co-twins. 
Pathway Name Nominal P Empirical P* 
Branched chain family amino acid metabolism 5.42E-08 0.0001 
Negative regulation of transcription 4.81E-07 0.0001 
Ligase activity, forming carbon-carbon bonds 2.21E-06 0.0001 
Branched chain family amino acid catabolism 6.26E-06 0.0002 
CoA carboxylase activity 7.11E-06 0.0002 
Water-soluble vitamin metabolism 8.29E-06 0.0004 
Muscle development 9.97E-06 0.0005 
*Empirical P-values interpreted from the distribution of 10,000 permutation cycles. 
 
Perhaps the most interesting findings came from interrogating the list of pathways 
down-regulated in the obeses co-twins (Table 10). The most significantly down-
regulated pathway was involved in the catabolism of branched-chain amino acids 
(BCAAs), namely valine, leucine and isoleucine. Incidentally it is specifically these 
amino acids (especially leucine) that act as insulin secretagogues following a 
protein-rich meal171 and are involved in the hypothalamic regulation of appetite 
through the mTOR signalling pathway (mammalian target of rapamycin)172. The 
role of BCAAs in obesity and the development of insulin resistance was first 
postulated  in the 1960s173 and their elevation in obese states has since been found in 
both rat-models of obesity174,175 and in humans176-179, but the related mechanism has 
not been settled. The possibility that in the obese, insulin resistant state the elevated 
BCAAs may serve as a feed-back signal to the pancreas to ensure an appropriately 
augmented secretory response was considered in the original report173, but no 
mechanism was suggested. The observation here in study IV of a clearly reduced 
catabolism of these BCAAs may provide this mechanism (Figure 24).  
Concordantly, along with the reduced catabolism of the BCAA’s, the total plasma 
concentrations of BCAAs were elevated in the obese co-twins (P=0.025) and their 
levels correlated significantly with fS-insulin (r=0.50, P=0.028). Further, the activity 
(mean-centroid) of the BCAA catabolism pathway correlated negatively with all 
measures of body fat, i.e., with liver fat (r=-0.56, p=0.002), subcutaneous fat (r=-
0.49, p=0.01) and intra-abdominal fat (r=-0.47, p=0.01). In a multiple regression 
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analysis including these fat depots, only liver fat remained significantly associated 
with the BCAA catabolism (R2 0.29). 
 
 
 
Figure 24. Postulated mechanism of the augmentation of insulin secretion in 
response to obesity associated insulin resistance.  FFA: free fatty-acid, BG: blood 
glucose, BCAA: branched chain amino acid. Modified from173. 
 
The possible role of mitochondrial heteroplasmy behind the discordance in BMI was 
excluded through complete sequencing of mitochondrial DNA. No known obesity-
predisposing mutations, or heteroplasmy could be detected between the co-twins. 
However, a considerable reduction in the mitochondrial DNA (mtDNA) copy number 
was observed in the obese co-twins –a novel finding in the study of human obesity. 
The mtDNA copy number in the obese co-twins was reduced to 53% of that in the 
non-obese co-twins (P=0.03). While reports exist of reduced mtDNA content in 
diabetic- and to a lesser extent in obese mice 180 and an impairment in the expression 
of  mitochondrial oxidative phosphorylation genes in type 2 diabetic muscle181 in 
humans, such a dramatic mtDNA loss in adipose tissue in human obesity is an entirely 
new observation. Interestingly the mitochondrial derangements including mtDNA loss 
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that was observed in the obese mice was only observed in adipose tissue, not in 
skeletal muscle or liver180. In study IV, no such differences in mtDNA content could 
be observed in leukocytes from the discordant twins, nor in the adipose tissue of 7 
concordant MZ twins studied, strongly suggesting that the mtDNA depletion in these 
twins is weight-dependent. With the observed inflammatory state of the adipose tissue 
in the obese and the known ability of inflammation and oxidative stress to cause 
mitochondrial dysfunction, the mtDNA loss may well be yet another manifestation of 
the inflammation. The disturbed mitochondrial morphology and protein profile 
observed in a mouse model of obesity (ob/ob) could be reversed by treatment with a 
thiazolidinedione (rosiglitazone)99 -the very same drug shown to downregulate SPP1 
expression170 that was here connected with the development of inflammation in 
adipose tissue. This observation may provide the link between inflammation and 
mitochondrial mtDNA depletion in obesity. 
A myriad of downstream effects of such a mitochondrial impairment could be 
hypothesized, among them a decreased maximal capacity for oxidative 
phosphorylation i.e. utilization of fat for energy production and a decreased 
catabolism of BCAAs –as this process takes place in mitochondria182. Decreased 
mitochondrial oxidative and phosphorylation activity may also result in the increase 
of intracellular fatty acid metabolites183. Such a dramatic decrease in the mtDNA 
content of the adipocytes of the obese, as here observed, surely has manifold 
sequelae that contribute to the multiple pathological features of the tissue, the 
precise consequences of which warrant further research. 
 
As this fourth work of the thesis was purely cross-sectional in nature, direction of 
causation between the observed changes cannot be directly inferred. However, 
samples and measurements were obtained from one obese study participant that had 
gained a significant amount of weight upon a follow-up visit. These data, while in 
essence amount to a case-report, do show convincingly a further progression toward 
the pathological in the very same measures identified as differing between the obese 
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and lean twins. Despite the limited sample size, this, in addition to the trend for 
increased effects in twins with greater obesity discordance lends support to the 
notion that the changes are indeed sequelae, not proximal causes of obesity. A note 
worth considering is the fact that the pathological changes observed here were found 
in young and otherwise healthy, but obese individuals –a testament to the real health 
risks associated with obesity. 
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CONCLUSIONS OF THE STUDY 
 
Shortly in reference to the aims listed for this thesis work on page 57, the following 
findings were presented: 
 
I. While the linkage signal extends into the neighboring F11R gene, the known 
function of USF1 and the functional evidence for the specific associated 
USF1 variant strongly indicate that USF1 is the associated gene underlying 
the linkage with FCHL in chromosome 1q21. 
II. The risk allele of the strongest associated SNP rs2073658 seems to eradicate 
the normal response of the USF1 gene to the inducing effect of insulin in 
peripheral tissues. This change in the USF1 transcription factor results in the 
differential expression of its target genes in adipose tissue. It is through these 
downstream effects that the increased risk for dyslipidemia and the 
development of coronary heart disease is thought to arise. 
III. Affected individuals from Finnish families with low-HDL carry rarer ABCA1 
variants more often then healthy control subjects, have higher expression of 
ABCA1 in their macrophage foam-cells concurrently with only marginally 
diminished efflux capacity. Defects in the early steps of the reverse transport 
of cholesterol may predispose to the development of premature coronary heart 
disease in Finnish families with low-HDL. 
IV. Numerous pathological changes can already be observed in the adipose tissue 
of young, obese but otherwise healthy individuals. Among the most prominent 
obesity associated changes were inflammation, a drastically diminished (63%) 
amount of mitochondrial DNA in adipocytes and a decreased catabolism of 
branched chain amino acids – a change that correlated strongly with liver fat 
and insulin resistance. The single most upregulated (5.9 –fold) gene in obesity 
was osteopontin (SPP1) – a cytokine involved in macrophage recruitment to 
adipose tissue and the development of insulin resistance. 
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CONCLUDING REMARKS 
 
This thesis work took place during an exciting time in the field of human genetics. 
Between the beginning of the project in 2003 and the present time, we celebrated the 
50th anniversary of the discovery of the structure of DNA, the essentially complete 
sequence of the human genome was revealed and the first genes behind complex 
disease were identified. The last few years have also seen the rise of genome-wide 
association studies that hold considerable promise for further discoveries and a 
deepened understanding of how genetic variation affects human health and disease 
on a global scale.  
 
The USF1 gene here investigated is one of the first examples of a gene identified 
underlying a complex human disease and it was discovered through the investigation 
of exceptional families segregating a multifaceted disease phenotype. The 
identification of USF1 as the associated gene in familial combined hyperlipidemia 
(FCHL) provides an example of how utilizing well described, extended families 
from a population isolate such as Finland continues to be a relevant and powerful 
tool in disease gene identification in this new era of complex genetics. This work 
also exhibits many of the challenges associated with complex disease gene research, 
among them the difficulty in identifying the functional defect(s) that may manifest 
themselves as only moderate perturbations to “normal” physiology and only under 
certain conditions, as well as the intellectual frustration that can arise from the 
inability to conclusively exclude the possibility of additional functional variants. 
Complex diseases such as the common dyslipidemias here investigated represent a 
continuum in phenotype in which at the extreme end an individual can be considered 
affected. This is often however an arbitrary delineation and as in the case of FCHL 
where the lipid phenotype of a patient can switch classes, a definite demarcation of 
affected versus non-affected is not necessarily meaningful. This underscores the 
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reality of the complex disease geneticists’ mantra that complex traits are a product 
of the interaction of a collection of genes with each other and the environment.  
As noted, during this thesis project a number of new complex disease gene variants 
have been identified in genome-wide association studies, but to date no functionality 
has been assigned to the identified variants. The scientific community keenly awaits 
further confirmation of the findings and ultimately for an explanation at the 
molecular level of how the variants affect the disease process. This should be the 
ultimate goal of research of this sort if one wishes to proceed from mere reports of 
association to a full understanding of the genetics involved and the possibility of 
developing interventions and treatments to better human health. 
The acquired component of complex disease is difficult to dissect in humans. To do 
this successfully requires an exceptional study sample and an unbiased global 
approach to analysis. The Finnish collection of monozygotic twins discordant for 
BMI was just such an exceptional sample that enabled the fine dissection of the 
molecular level events that take place in acquired obesity. In addition to confirming 
known events such as inflammation of adipose tissue, the study was able to shed 
light on completely novel aspects of the processes involved in the progression to 
insulin resistance and other pathological sequelae of obesity. 
 
A common theme through this thesis work has been dyslipidemia, both in its 
familial and acquired forms. In addition, the USF1 transcription factor, somewhat 
serendipitously turns out to be a common thread in the four works comprising this 
thesis; USF1 is the first gene associated with FCHL and as a transcription factor it is 
involved in the transcriptional regulation of ABCA1 (here shown to be involved in 
the pathogenesis of low-HDL) as well as SPP1 (here shown to be the most 
differentially expressed gene in obesity). In addition to highlighting the wide-
ranging role of this transcription factor, this hints at the immense, interconnected 
network of genes and their interactions that is a key concept in beginning to 
understand the molecular background of complex disease. 
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